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 Semi-synthetic β-lactam antibiotics are the most prescribed class of antibiotics in 
the world.  Chemical coupling of a β-lactam moiety with an acyl side chain has 
dominated the industrial production of semi-synthetic β-lactam antibiotics since their 
discovery in the early 1960s.  Enzymatic coupling of a β-lactam moiety with an acyl side 
chain can be accomplished in a process that is much more environmentally benign but 
also results in a much lower yield.  The lower yield in the enzymatic synthesis can be 
attributed to the fact that the enzymes that catalyze the reaction, penicillin G acylase 
(PGA) or α-amino ester hydrolase (AEH), have the ability to catalyze the undesired 
primary hydrolysis of the side chain acyl donor and the secondary hydrolysis of the 
antibiotic, in addition to the desired synthesis reaction.  The goal of the research 
presented in this dissertation is to improve the enzymatic synthesis of β-lactam antibiotics 
via reaction engineering, medium engineering and data-driven protein engineering.   
 Reaction engineering was employed to demonstrate that the hydrolysis of 
penicillin G to produce the β-lactam nucleus 6-aminopenicillanic acid (6-APA), and the 
synthesis of ampicillin from 6-APA and (R)-phenylglycine methyl ester ((R)-PGME), can 
be combined in a cascade conversion.  In this work, PGA was utilized to catalyze the 
hydrolysis step, and PGA and AEH were both studied to catalyze the synthesis step.  Two 
different reaction configurations and various relative enzyme loadings were studied.  In 
all reaction configurations the two-enzyme system that utilized PGA and AEH out-
performed the one-enzyme system that utilized only PGA.  The one-pot, two step system, 




addition of the acyl donor and AEH catalyzed synthesis, achieved 47%, yield and 
secondary hydrolysis was minimized by optimizing relative enzyme loadings.  The one-
pot, one-step system, a batch process in which all substrates and enzymes are present at 
the beginning of the reaction, achieved 39% yield, but could be advantageous due to its 
operational ease and faster cycle times. Both configurations present a promising 
alternative to the current two-pot set-up which requires intermittent isolation of the 
intermediate, 6-aminopenicillanic acid (6-APA).   
 Medium engineering is primarily of interest in β-lactam antibiotic synthesis as a 
means to suppress the undesired primary and secondary hydrolysis reactions.  The 
synthesis of ampicillin from 6-APA and (R)-PGME in the presence of ethylene glycol 
was chosen for study after a review of the literature.  It was found that the yield 
enhancement observed in syntheses in 30% (v/v) ethylene glycol was dependent on the 
amount of (R)-PGME used for the reaction.  Furthermore, it was discovered that the 
transesterification product of (R)-PGME and ethylene glycol, (R)-phenylglycine 
hydroxyethyl ester ((R)-PGHEE), is transiently formed during the synthesis reactions.  
This never reported side reaction has the ability to positively affect yield by re-directing a 
portion of the consumption of (R)-PGME to an intermediate that could be used to 
synthesize ampicillin, rather than to an unusable hydrolysis product.  (R)-PGHEE was 
synthesized and its ability to act as an acyl side chain donor for ampicillin synthesis was 
confirmed.  Also, ampicillin synthesis was performed with (R)-phenylglycine amide, an 
acyl side chain donor that does not undergo transesterification by ethylene glycol, and the 
ampicillin yield enhancement in 30% (v/v) ethylene glycol was found to be minimal.  




positively affect yield by participating in an in-situ mixed donor process, where both (R)-
PGME and (R)-PGHEE contribute to the synthesis of ampicillin.   
 Protein engineering was utilized to alter the selectivity of wild-type PGA with 
respect to the alpha carbon of its substrates.  This work represents the first time that the 
selectivity of PGA has been studied to synthesize a diastereomerically pure β-lactam 
antibiotic from racemic substrates.  Using existing crystal structures of PGA, residues 
were targeted for site-saturation based on their proximity to the alpha carbon of the 
inhibitor penicillin G sulfoxide.  Four residues were identified that had altered selectivity 
toward the desired product, (R)-ampicillin.  The most selective variant, βPhe24Ala, 
improved the wild-type diastereomeric excess (d.e.) value from 37% to a d.e. value of 
98%.  Furthermore, our (R)-selective variants improved the yield from pure (R)-PGME 
up to 2-fold and significantly decreased the amount of secondary hydrolysis present in 
the reactions.  Protein engineering techniques should be pursued to further improve the 
selectivity of these PGA variants to a d.e. value greater than 99.8% in order to eliminate 
the need to prepare enantiomerically pure substrates for semi-synthetic β-lactam 
antibiotics.   
 Overall, we have expanded the applicability of PGA and AEH for the synthesis of 
semi-synthetic β-lactam antibiotics.  We have shown the two enzymes can be combined 
in a novel one-pot cascade, which has the potential to eliminate an isolation step in the 
current manufacturing process.  Furthermore, we have shown that the previously reported 
ex-situ mixed donor synthesis of ampicillin for PGA can also occur in-situ in the 




significant progress towards obtaining a selective PGA that is capable of synthesizing 









In 2005, the American Chemical Society Green Chemistry Institute (ACS GCI) 
and representatives from seven leading global pharmaceutical companies formed the 
ACS GCI Pharmaceutical Roundtable (ACS GCIPR) and defined their mission as 
catalyzing “the implementation of green chemistry and green engineering in the global 
pharmaceutical industry,” acknowledging the fact that the “the pursuit of green chemistry 
and green engineering is imperative for sustainable business and environment.”  The 
members of the ACS GCIPR voted amide formation avoiding poor atom economy 
reagents as the highest priority for reactions that companies use now but would strongly 
prefer better reagents [1].  Included in this group of reactions is the synthesis of semi-
synthetic β-lactam antibiotics.   
 
1.1 β-Lactam Antibiotics 
β-lactam antibiotics have been in clinical use for more than 60 years and are 
currently the most widely used group of antibiotics utilized to treat bacterial infections.  
The common moiety of all β-lactam antibiotics is a 2-azetidinone ring, more commonly 
referred to as the β-lactam ring, which is responsible for their bactericidal capabilities [2].  
There are four sub-families of the β-lactam antibiotic family that are currently used in 
clinical practice: the penicillins, cephalosporins, carbapenems, and monobactams, which 
vary in their ring structure around the β-lactam ring to form unique β-lactam nuclei as 
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structure results in growth inhibition, cell lysis, and ultimately cell death.  β-lactam 
antibiotics can work on both gram-positive and gram-negative bacteria, but in gram-
negative bacteria they must penetrate the cell membrane to get into the cell periplasm to 
access the penicillin-binding proteins [4].  Even though they are active against a wide 
range of bacterial pathogens, they have shown very little toxicity to mammalian cells, a 
fact which has contributed greatly to their success in clinical practice [2].  
 
Over time, pathogens have developed resistance to β-lactam antibiotics in four 
ways [2, 4, 9]: 
1.) Pathogenic strains produce β-lactamases, enzymes that catalyze the hydrolysis 
of the β-lactam ring and render the antibiotic ineffective. 
2.) Pathogenic strains produce mutated penicillin-binding proteins to decrease their 
binding affinity for the β-lactam ring. 
3.) Gram-negative pathogenic strains downregulate their porin channels to limit the 
entry of the antibiotic into the periplasmic space and thus block their access to 
the penicillin-binding proteins. 
4.) Pathogenic strains are able to force the efflux of the antibiotic from the cell 
cytosol. 
Perhaps the most drastic case of antibiotic resistance is the case of methicillin-
resistant Staphylococcus aureus, which has developed resistance by way of 
downregulation of its porin channels.  However, the most common reason for antibiotic 
resistance is the bacterial strains’ production of β-lactamases [4, 6].  To date, there are 
more than 450 known β-lactamases.  β-lactamases can be expressed in both gram-
4 
 
negative and gram-positive bacteria and be either constitutively expressed or induced by 
exposure to β-lactam antibiotics [6].  In some cases, the effect of β-lactamases can be 
suppressed by administering a β-lactamase inhibitor along with the antibiotic.  FDA 
approved inhibitors include sulbactam, tazobactam and clavulanate [10].  
Despite the growing resistance to β-lactam antibiotics, their use in clinical 
practices to treat bacterial infections remains prevalent.  In 2003 they comprised about 
65% of the total world market for antibiotics, with cephalosporin dosage sales estimated 
to be $9.9 billion and penicillin dosage sales estimated to be $5 billion [11].  
Furthermore, about half of the antibacterials listed on the World Health Organization’s 
Model List of Essential Medicines are β-lactam antibiotics, with seven on the core list of 
medicines that are needed for a basic health care system and three on the complementary 
list of medicines that are needed for priority diseases.  The core list medicines are 
considered to be the most safe, efficacious, and cost-effective medicines for current and 
future health care [12].    
 
1.2 Synthesis Techniques for Semi-Synthetic β-Lactam Antibiotics 
 Only two β-lactam antibiotics that are used in clinical practice, penicillin G and 
penicillin V, are products of a fermentation process and thus considered to be naturally 
occurring molecules. The majority of β-lactam antibiotics used in clinical practices are 
classified as semi-synthetic because the β-lactam moiety is obtained from the enzymatic 
hydrolysis of a natural fermentation product; penicillin G, penicillin V, or cephalosporin 




1.2.1 Chemical Synthesis 
Chemical coupling of the β-lactam moieties with an acyl side chain has dominated 
the industrial production of semi-synthetic β-lactam antibiotics since their discovery in 
the early 1960s.  The majority of semi-synthetic β-lactam antibiotics are still synthesized 
by way of the Dane anhydride process, which can achieve yields as high as 90% [13].  
This process is carried out at temperatures as low as -30oC, uses highly reactive pivaloyl 
choride and silylating protection groups, and requires large volumes of dichloromethane, 
triethylamine and acetone for solvents.  Despite recycling solvents and auxiliary reagents 
where possible, the Dane anhydride process still generates a large amount of non-
biodegradable waste.  Specifically, 30 kg to 40 kg of solid waste are generated for every 
kg of product in the synthesis of cephalexin [14].   
 
1.2.2 Biocatalytic Synthesis 
 The coupling of the β-lactam nuclei with the acyl side chain can be accomplished 
enzymatically utilizing penicillin G acylase (PGA).  A less studied enzyme, α-amino 
ester hydrolase (AEH), can also be used for this reaction when the acyl side chain has an 
amino group in the α-position.  Furthermore, the coupling can be carried out under 
thermodynamic control, which utilizes a non-activated acyl side chain, or kinetic control, 
which requires an activated side chain (typically an ester or amide).  The 
thermodynamically-controlled and kinetically-controlled syntheses will be discussed in 
further detail in Chapter 2. 
 The first published example of the biocatalytic coupling of β-lactam antibiotics on 
an industrial scale was not until 1997 when DSM (Delft, Netherlands) opened a 
6 
 
production plant for cephalexin, marketed as Purilex®, in Barcelona, Spain.  Initially it 
was reported that the penicillin acylase-catalyzed coupling reaction is performed in water 
between 0oC and 20oC with varying stoichiometric ratios of the nucleus and activated 
acyl side chain.  The enzymatic coupling only achieved 40-60% conversion per cycle and 
had to be followed by several isolation and recycle steps  [14].  Further reports indicate 
that the yields of the enzymatic coupling were able to be improved by using substrate 
concentrations as high as 0.3 to 0.5 M and using an excess of the activated acyl side chain 
[15].  DSM has since expanded their production of enzymatically synthesized β-lactam 
antibiotics under the umbrella name of DSMPureActivesTM to also include amoxicillin, 
marketed as Purimox®, and cefadroxil, marketed as Puridrox® [16].   
 
1.3 Comparison of Synthesis Techniques for Semi-Synthetic β-Lactam Antibiotics 
 The obvious disadvantage of the enzymatic coupling process in comparison to 
chemical coupling process is the lower yield of the product.  However, the enzymatic 
coupling has undeniable advantages over the chemical coupling in terms of cost of raw 
materials, environmental impact, product quality, and ease of processing; due to the fact 
that it is carried out at ambient temperature, pressure and pH; and does not require toxic 
or hazardous reagents or solvents [13].    From an environmental standpoint, by switching 
from the chemical coupling to the enzymatic coupling, DSM has reduced process 
greenhouse emissions by over 50%, reduced process emissions to water by 50%, and 
reduced process waste by 90%.  From a product quality standpoint, it has increased the 
average purity by 1.6%, 1.4%, and 1.2% as assayed “on dry” high performance liquid 
chromatography for Purimox®, Purilex® and Puridrox®, respectively.  For an example 
7 
 
of the impurities eliminated by switching to the biocatalytic coupling in the production of 
cefadroxil, see Table 1.1.  Furthermore, they report an increased shelf life of the 
enzymatically synthesized products and better tasting end products for patients.   From a 
processing standpoint, DSM has reduced the number of processing steps by 50% and 
increased the size of batch production by at least 3-fold and as much as 10-fold.   The 
decrease in number of impurities and increase in the size of batch production translates 
into a significant reduction in the amount of quality control testing that is required for all 
pharmaceutical products [16].  
 
 
Table 1.1: Comparison of impurities present in the enzymatically-coupled antibiotic Puridrox® and the 
industrial average for chemically-coupled cefadroxil [16]. 
Impurity Impurity Source Puridrox® Industry 
Average 
acetone  (%) solvent < 0.01 0.01-0.08 
methylene chloride (ppm) solvent NP 1.5-100 
pivalic acid (ppm) solvent NP <10 
dimethylformamide (%) solvent NP 0.0-0.37 
(R)-hydroxyphenylglycine undesired product 0.03-0.07 0.04 
7-aminodesacetoxycephalosporanic  
   Acid 




1.4 Biocatalysts Used to Synthesize β-Lactam Antibiotics 
1.4.1 Penicillin G Acylases  
 As discussed previously, PGA (EC 3.5.1.11) is a very important enzyme in the 
industrial production of semi-synthetic β-lactam antibiotics, as it is used to obtain the β-
lactam nuclei from naturally occurring antibiotics and can be used for the coupling of the 
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 Like all Ntn hydrolases, PGA is expressed as an inactive precursor peptide that 
must undergo post-translational processing to render the mature form [20].  Specifically, 
PGA is expressed as a single cytoplasmic precursor which contains an N-terminal 26 
amino acid signal sequence, a 209 amino acid α-chain, a 54 amino acid spacer sequence, 
and a 557 amino acid β-chain.  The signal sequence is responsible for the protein’s 
transport from the cytoplasm and is cleaved upon the protein’s arrival into the periplasm.    
The linker sequence aids in the protein’s folding and is subsequently cleaved to expose 
the active residue.  Both the sequence and linker cleavage processes are believed to be 
autocatalytic [19, 20, 22].  Interestingly, a precursor peptide mutated to undergo slow 
post-translational processing has shown that the periplasmic precursor protein has an 
almost identical fold to mature PGA, the two forms have only a 0.71 Å r.m.s. difference 
between the alpha carbons in their α and β chains.  The periplasmic precursor protein 
crystal structure shows that the linker peptide is compactly packed against the surface 
depression and the active site observed in mature PGA [22].   
 The catalytic mechanism of PGA has been elucidated through crystal structures 
and mutagenesis studies.  PGA has a hydrophobic binding pocket lined with aromatic and 
hydrophobic residues that is specific for phenylacetyl groups and their derivatives [19-
21].  The range of substrate specificity and enantioselectivity of PGA for phenylacetyl 
derivatives is determined by the size and polarity of their substituents [23].  Residues in 
the active site undergo a conformational shift upon substrate binding to create a binding 
site for the penicillin nucleus, therefore, PGA substrate binding is an induced fit 
mechanism [19, 20, 24, 25].  Bound substrates are in the proper position for the catalytic 
serine, located at the β1 position, to perform a nucleophilic attack on the carbonyl carbon 
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of the substrate to form an oxyanion tetrahedral transition state and subsequently a acyl-
enzyme intermediate [21].  A nucleophile, which can be a β-lactam nucleus for a 
coupling reaction, or water for a hydrolysis reaction, then deacylates the acyl-enzyme 
intermediate to form products.  PGA’s residues that are important for catalysis and their 
respective functions are listed in Table 1.2.  As shown in Table 1.2, mutation of the active 
site residues frequently leads to a buildup of the inactive precursor in the periplasm, 
indicating that the residues that participate in catalysis also participate in the autocatalytic 
cleavage of the linker peptide [19, 24, 25].  Crystal structures of a PGA mutant 
undergoing slow post-translational processing agree with this fact [22].   
 
1.4.1.2 Kinetic Parameters of Penicillin G Acylases 
 The kinetic parameters of PGA are shown in Table 1.3.  Ideally, the activity of 
PGA for the β-lactam antibiotic would be much lower in comparison to the activated acyl 
side chains so as to enhance the rate of the coupling reaction and decrease the rate of the 
hydrolysis reactions that occur in the kinetically-controlled synthesis of β-lactam 
antibiotics.  However, the kinetic parameters reported show that instead kcat/Km values of 
the antibiotic are about 10 times higher than that of the activated acyl side chains [26, 









Table 1.2: Important residues for catalysis in PGA from E. coli.   
Residue Function Source 
αMet142 Interacts with phenylacetyl side-chain of substrate. [19] 
αArg145 
 
Able to have two different conformations:  
1)'Closed' helical conformation: no substrate is bound; residue 
side-chain is hydrogen bonded to βPhe24  
2) 'Open' coil conformation: bound substrate; residue side-chain 
interacts with carboxylate oxygen of β-lactam nucleus via two 
bridging water molecules. 
 
Mutation to Leu, Cys, or Lys results in correctly processed mutant 
but a 5-50 fold reduction in kcat/Km for the chromogenic reference 





Able to have two different conformations:  
1)'Closed' helical conformation: no substrate is bound; residue 
closes hydrophobic active site from solvent  
2) 'Open' coil conformation: bound substrate; side-chain interacts 
with β-lactam nucleus. 
 
Structurally linked to βPhe71 via a calcium ion. 
 






Acts as catalytic residue by performing nucleophilic attack on 
substrate's carbonyl group to form oxyanion tetrahedral transition 
state.  
 
In proper position to perform nucleophilic attack that cleaves 
linker peptide. 
 
Mutation to an Ala results in accumulation of precursor protein. 
 
Mutation to a Cys results correct processing but Cys is susceptible 





Main chain amide stabilizes tetrahedral intermediate by forming 
part of oxyanion hole. 
 
Main chain oxygen might have van der Waals interactions with 
carboxyl oxygen of β-lactam ring. 
 
Main chain amide thought to be in proper position to stabilize 
tetrahedral transition state in linker cleavage reaction by forming 







Table 1.2 continued: Important residues for catalysis in PGA from E. coli. 
Residue Function Source 
βPhe24 
 
Interacts with phenylacetyl side-chain of substrate. 
 
Limits the size of the Cα-substituent that can bind in phenylacetic 
acid derivatives. 
[19, 23] 
βSer67 Side chain interacts with hydroxyl group in p-
hydroxylbenzylpenicillin and increases the rate of hydrolysis 




Main chain amide stabilizes tetrahedral intermediate by forming 
part of oxyanion hole. 
 
Main chain amide thought to be in proper position to stabilize 
tetrahedral transition state in linker clevage reaction by forming 





Slightly changes conformation upon binding with substrate to 
form a stacked conformation with thiazolidine ring of β-lactam 
nucleus. 
 
Structurally linked to αPhe146 via a calcium ion. 
[19, 24] 
βIle177 Interacts with phenylacetyl side-chain of substrate. [19] 
βAsn241 
 
Nδ stabilizes tetrahedral transition state by forming part of 
oxyanion hole. 
 
Nδ thought to be in proper position to stabilize tetrahedral 
transition state in linker cleavage reaction by forming part of 
oxyanion hole. 
 
Aides in positioning bound substrate, especially the appropriate 
placement of the amide bond for catalysis. 
 





Residue must be protonated for catalysis to occur as the charge 
effects the electrostatic environment of oxyanion hole and could 
possibly affect transition state stabilization. 
 
Interacts with β-lactam nucleus of the substrate through salt 
bridge. 
 
Mutation to an Ile, Leu or Asn results in accumulation of 
precursor protein. 
 
Mutation to a Lys results in partially processed precursor protein, 




Table 1.3: Selected kinetic parameters for PGA from E. coli.  










    amide 
27.4 35.6 1.3 30 7.0 [28, 29] 
(R)-phenylglycine   
    methyl ester 
12.5 50 4 30 7.0 [27] 
ampicillin 3.6 36.7 10.19 30 7.0 [28, 29] 
cephalexin 1.5 29 19.3 30 7.0 [30] 
amoxicillin 1.07 17 15.9 30 7.0 [30] 
cefadroxil 0.642 32 49.8 30 7.0 [30] 




1.4.1.3 Protein Engineering of Penicillin G Acylases 
 The majority of protein engineering of PGA has targeted increasing the synthesis 
of the antibiotic and decreasing the primary hydrolysis of the activated acyl side chain 
and the secondary hydrolysis of the antibiotic in the biocatalytic coupling of the β-lactam 
nucleus and the activated acyl side chain.  Alkema et al. and Jager et al. have attempted 
this feat with both rational and combinatorial design but have had limited success [25, 26, 
28, 29].  Alkema et al. examined the role of residue αArg145 and βArg263 using site-
directed mutagenesis (the amino acid residues are labeled to indicate the chain, α or β, the 
wild-type amino acid residue, the reside number on the chain, and the variant amino acid 
residue when applicable).  αArg145 variants showed an increase in affinity for the β-
lactam nucleus as a nucleophile compared to water at the expense of significantly 
decreased activity.   βArg263 was determined to be important for precursor processing 
but not involved in substrate binding [25].  Jager et al. examined the importance of 
αArg145 and αPhe146 on PGA nucleophile selectivity via site-saturation mutagenesis.  
These residues were chosen based on the fact that crystal structures show that they 
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undergo a 3.5 Å conformational shift towards the solvent upon ligand binding.  Both sets 
of variants had improved synthesis to hydrolysis ratios but again at the expense of 
activity.  For example the αArg145Trp variant had synthesis to hydrolysis ratio of 14.3, 
nearly a 10-fold increase over the wild-type enzyme, but showed only 6% of the wild-
type PGA activity [29].   
 Protein engineering on PGAs has also been employed to improve its 
thermostability.  Polizzi et al. used the structure-guided consensus concept to target 
potentially thermostabilizing mutations on 20 residues.  Of these variants, 50% had an 
increased half-life at 50oC, 10% had a half life equivalent to that of the wild-type 
enzyme, 20% had a decreased half-life and the remaining variants’ activity was too low 
to determine an accurate half-life.  Variants αTrp25Tyr and αAla80Arg improved the 
half-life of PGA by about 2.5 and the activity by about 1.5 in comparison to wild-type 
PGA [31].   
 
1.4.2 α-Amino Ester Hydrolases 
 AEHs (E.C. 3.1.1.43), also referred to as ampicillin acylases, are a family of 
enzymes that are interesting because they are capable of the synthesis and hydrolysis of 
semi-synthetic antibiotics [32-36].  In other words, they are alternatives to PGAs.  As 
their name implies, AEHs are highly specific for substrates which contain an α-amino 
substituent, such as ampicillin and cephalexin.  In fact, they have been shown to 
hydrolyze β-lactam antibiotics containing an α-amino group, with a twofold higher 
activity compared to penicillin G [37].  Their unique substrate specificity renders them 
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 AEHs are unique in that an acidic cluster, Asp-Glu-Asp, termed a carboxylate 
cluster, has been identified in the active site of the protein.  This cluster is associated with 
the enzyme's unique α-amino substrate specificity [34, 40, 41].  AEHs are very substrate-
specific for α-amino acid derivatives, such as ampicillin, but can accept the cephalosporin 
β-lactam nuclei 7-aminocephalosporanic acid (7-ACA) and 7- 
aminodeacetoxycephalosporanic acid (7-ADCA), or the penicillin β-lactam nucleus 6-
aminopenicillanic acid (6-APA) with some preference for 7-ADCA.  The enzyme has no 
detected activity for penicillin G which lacks an α-amino substituent [33, 41-43].  
 
1.4.2.2 Kinetic Parameters of α-Amino Ester Hydrolases 
 AEHs were evaluated for use in the synthesis of the cephalosporins cephalexin 
and cephaloglycine from (R)-phenylglycine methyl ester ((R)-PGME) and 7-ACA or 7-
ADCA, respectively [32, 33]. The kinetic parameters for AEHs are shown in Table 1.4.  
Several organisms were used in Takahashi’s studies, however, the highest product 
concentrations were obtained from the strains IFO 3835 from X. citri and ATCC 9325 
from A. turbidans [32, 33, 42]. 
 
1.4.2.3 Protein Engineering of α-Amino Ester Hydrolases 
 The synthesis parameters have been reported in the synthesis of cephalexin from 
7-ADCA and (R)-PGME. Conversions as high as 75% have been reported with a non-
recombinant preparation of AEH from X. citri under optimized conditions [44]. Barends 
reported that mutating the tyrosine adjacent to the catalytic serine to alanine, Tyr206Ala, 
improved its initial synthesis to hydrolysis ratio and improved its maximum product yield 
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from 36% to 58% conversion in a reaction containing 15 mM (R)-PGME and 30 mM 6-
APA [35]. However, there is still significant room for improvement on these enzymes’ 
synthesis parameters.  Very little work has been done on optimizing the reaction 
conditions and very little protein engineering has been attempted with the AEHs.  
 
 
Table 1.4. Selected kinetic parameters for AEHs.  











(R)-phenylglycine amide >13 >43 3.3 30 6.0 [40] 
(R)-phenylglycine methyl ester 7 1035 148 30 6.0 [40] 
ampicillin 1.0 162 162 30 6.0 [40] 
cephalexin 0.34 347 1021 30 6.0 [40] 
amoxicillin 2.6 10 3.9 30 6.0 [40] 
cefadroxil 1.7 9.6 6 30 6.0 [40] 
X. citri 
(R)-phenylglycine amide ND 1.6 - 25 6.4 [34] 
(R)-phenylglycine methyl ester 90 1860 21 25 6.4 [34] 
ampicillin 1.2 58 48 25 6.4 [34] 
cephalexin 1.8 160 89 25 6.4 [34] 
amoxicillin - - 2 25 6.4 [34] 
cefadroxil - ND - 25 6.4 [34] 
penicillin G - ND - 25 6.4 [34] 
X. campestris pv. campestris 
ampicillin 1.1 72.5 64.5 25 6.8 [45] 
cephalexin 2.2 200 95 25 6.8 [45] 







1.5 Research Objectives and Organization 
 The overarching goal of the research presented in this dissertation is to investigate 
methods that will lead to an improvement in the enzymatic synthesis of semi-synthetic β-
lactam antibiotics.  Specifically, we sought to improve the enzymatic synthesis of semi-
synthetic β-lactam antibiotics with three different approaches: reaction engineering, 
medium engineering, and data-driven protein engineering.  Our studies primarily focus 
on the penicillin G acylase-catalyzed kinetically-controlled synthesis of ampicillin from 
the acyl side chain (R)-phenylglycine methyl ester and the β-lactam nucleus 6-
aminopencillianic acid, though some variations in the catalyst and acyl side chain donors 
utilized will be discussed.  Though focused on ampicillin synthesis, the research results 
presented could be applicable to the synthesis of amoxicillin, cephalexin, cefadroxil, 
cefaclor, and cefprozil.   
  
1.5.1 Improving the Enzymatic Synthesis of Semi-Synthetic β-Lactam Antibiotics via 
Reaction Engineering 
  
 Chapter 2 of this dissertation will begin with a discussion of the 
thermodynamically-controlled and kinetically-controlled enzymatic syntheses of semi-
synthetic β-lactam antibiotics.  Subsequently, the feasibility of utilizing a cascade 
conversion involving two biocatalytic steps in fully aqueous medium to produce 
ampicillin will be presented.  The cascade conversion seeks to combine the production of 
the β-lactam nucleus 6-APA from penicillin G utilizing immobilized PGA and the 
synthesis of ampicillin from 6-APA and (R)-PGME utilizing either AEH or immobilized 
PGA.  This set-up presents a promising alternative to the current two-pot set-up which 
requires intermittent isolation of the intermediate, 6-APA.      
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 In this work, two different reaction configurations and various relative enzyme 
loadings were studied.  In a one-pot, one-step configuration, a batch process, penicillin G, 
(R)-PGME, and all enzyme(s) were added to the reaction and the reaction was allowed to 
proceed.  In a one-pot, two-step configuration, penicillin G and PGA were added to the 
reaction and the hydrolysis reaction was allowed to proceed.  When the hydrolysis 
reaction was near completion, (R)-PGME and either AEH or PGA was added to the 
reaction.  The choice of enzymes and the effect of relative enzyme loadings for each set-
up will be presented, and the disadvantages and benefits of each set-up will be discussed.   
 
1.5.2 Improving the Enzymatic Synthesis of Semi-Synthetic β-Lactam Antibiotics via 
Medium Engineering 
 
 Initially, the synthesis of ampicillin in organic co-solvents was chosen for 
investigation due to the known advantages of enzymatic syntheses in organic co-solvents 
which include increased solubilities of reactants and products, shifting reaction equilibria, 
and most important for the enzymatic coupling step in β-lactam antibiotic synthesis, 
suppressing hydrolysis reactions.  Ethylene glycol was chosen as a starting point after a 
review of the literature. In Chapter 3 of this thesis, the effects of performing the synthesis 
of ampicillin in the presence of an ethylene glycol co-solvent will be presented.   
 Interestingly, it was determined that the benefit of utilizing ethylene glycol as a 
co-solvent varies for different starting ratios of 6-APA to (R)-PGME.  Additionally, it 
was determined that the transesterification product of (R)-PGME and ethylene glycol, 
(R)-phenylglycine hydroxyethyl ester ((R)-PGHEE), was forming during the synthesis 
reactions.  In contrast, the formation of (R)-PGHEE was not observed in the synthesis of 
ampicillin from 6-APA and (R)-phenylglycine amide.  In this work, the results for 
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synthesis of ampicllin in ethylene glycol from 6-APA and different acyl side chains will 
be compared in order to demonstrate the effects of (R)-PGHEE formation on the overall 
yield observed in the kinetically-controlled synthesis of ampicillin. 
 
1.5.3 Improving the Enzymatic Synthesis of Semi-Synthetic β-Lactam Antibiotics via 
Data-Driven Protein Engineering 
  
 Chapter 4 of this dissertation will discuss how data-driven protein engineering 
was employed to improve the diastereomeric selectivity of PGA.  Specifically, the 
selectivity of PGA with respect to the amino group on the alpha carbon in the synthesis of 
ampicillin from racemic phenylglycine methyl ester (rac-PGME) and 6-APA was 
targeted for improvement. Currently, when starting with rac-PGME, PGA is only weakly 
selective for the desired product, (R)-ampicillin, over the undesired product, (S)-
ampicillin.  Development of a selective PGA would enable the use of racemic acid 
derivatives in β-lactam antibiotic synthesis.   
 In order to alter the selectivity of PGA, five residues in the active site were chosen 
for randomization.  All five libraries were screened and positive hits were subsequently 
sequenced and characterized in reactions with rac-PGME and pure PGME enantiomers.  
The explanation of improved selectivity properties observed in PGA variants will be 
presented based on existing knowledge of PGA crystal structures and mutagenesis 
studies.   
 
1.6 Publication Information 
 The review of β-lactam antibiotics, the associated synthesis techniques, and 
biocatalysts involved is published in Wiley’s Encyclopedia of Industrial Biotechnology 
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(Ed. M.C. Flickinger, 2010, pp 535-567) with Janna K. Blum and Andreas S. Bommarius 
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IMPROVING THE ENZYMATIC SYNTHESIS OF β-LACTAM ANTIBIOTICS 




2.1 Introduction  
2.1.1 Enzymatic Synthesis of Semi-Synthetic β-Lactam Antibiotics 
 Semi-synthetic β-lactam antibiotics are classified as such because their β-lactam 
moiety is obtained from a natural fermentation product and their acyl side chain is 
obtained from a chemical or chemoenzymatic synthesis.  As mentioned in Chapter 1, the 
enzymatic coupling of an acyl side chain with a β-lactam nucleus can be accomplished 
utilizing either penicillin G acylase (PGA) or α-amino ester hydrolase (AEH).  
Regardless of the biocatalyst chosen, the synthesis of β-lactam antibiotics can be carried 
out under thermodynamic control, which utilizes a non-activated acyl side chain, or 
kinetic control, which requires an activated side chain (typically an ester or amide).  See 
Figure 2.1 for a comparison of the thermodynamic and kinetic enzymatic syntheses of 
ampicillin.  
The thermodynamically-controlled synthesis, also referred to as the direct or 
equilibrium-controlled synthesis, is only able to achieve minimal yields (1% or less) in 
aqueous medium, as the equilibrium lies very far to the left [1-4].  At typical reaction 
conditions the substrates are in their ionized forms, which PGA does not accept [2, 4].  
Therefore, the thermodynamically-controlled enzymatic synthesis usually has very slow 
rates in addition to very low yields.  Adding organic co-solvents to decrease the water 










Figure 2.1: The PGA catalyzed coupling of ampicillin via A) a thermodynamically-controlled route starting 
from (R)-phenylglycine ((R)-PG) and 6-aminopenicillanic acid (6-APA) and B) a kinetically-controlled 









success [1-4].  For example, in the case of cephalexin synthesis, the yield was only 
improved from 0.75% in aqueous medium to 1.25% in 36% (v/v) triglyme [4].  
Though the thermodynamically-controlled system is not useful for the synthesis 
of semi-synthetic β-lactam antibiotics, the equilibrium is taken advantage of to synthesize 
the β-lactam nucleus 6-aminopenicillanic acid (6-APA) though the hydrolysis of the 
naturally occurring penicillin G using PGA or penicillin V using penicillin V acylase (EC 
3.5.1.11).  6-APA is the β-lactam nucleus used to synthesize all semi-synthetic 
penicillins.  Furthermore, its five-membered ring can be expanded to a 6-membered ring 
to generate 7-aminodesacetoxycephalosporanic acid (7-ADCA), the β-lactam nucleus for 
a number of cephalosporins [5]. In 2003, 6-APA was the world’s largest selling β-lactam 
intermediate with a worldwide production of 8,800 tons per year [5, 6]. 
 Typically, the kinetically-controlled synthesis is employed for the coupling of the 
β-lactam nuclei and the acyl side chain.  However, the kinetically-controlled reaction 
results in low yields (between 30 and 40%) because PGA catalyzes the undesired primary 
hydrolysis of the activated acyl side chain donor and the secondary hydrolysis of the 
antibiotic in addition to the desired synthesis reaction (again, refer to Figure 2.1).  This 
phenomenon can be explained by the specificity and catalytic mechanism of PGA 
described in Chapter 1.  As PGA is specific for only the phenylacetyl portion of its 
substrates, acyl side chains and β-lactam antibiotics both bind to the enzyme.  These 
electrophilic substrates are attacked by the catalytic serine of PGA and an acyl-enzyme 
intermediate is formed.  Subsequently a nucleophile, which can be a β-lactam nucleus for 
a coupling reaction or water for a hydrolysis reaction, deacylates the acyl-enzyme 
intermediate to form products.   
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2.1.2 One-Pot Synthesis of Semi-Synthetic β-Lactam Antibiotics 
 Cascade conversions, which combine multiple reactions without intermediate 
recovery steps, are increasingly studied to render syntheses more environmentally benign 
and economically advantageous.  Replacing a multi-step synthesis requiring intermittent 
isolation with a cascade process eliminates the need for isolation and purification of 
intermediates and therefore results in smaller reactor volumes, shorter cycle times, higher 
volumetric and space time yields, and decreased amount of waste produced [7, 8]. 
Cascade conversions can combine multiple biocatalytic steps, multiple chemocatalytic 
steps, or can combine both biocatalytic and chemocatalytic steps. Typically it is easiest to 
combine multiple biocatalytic steps as most enzymes have similar operating conditions 
[7].  There have been several reports of utilizing cascade processes for semi-synthetic β-
lactam antibiotic synthesis.  Wegman et al. combined the synthesis of the acyl side chain 
(R)-phenylglycine amide from (R)-phenylglycine nitrile utilizing nitrile hydratase and the 
enzymatic coupling of (R)-phenylglycine amide with the β-lactam nucleus 7-ADCA 
utilizing PGA to synthesize cephalexin in a one-pot synthesis[9].  Fernández-Lafuente et 
al. reported a chemoenzymatic synthesis of cefazolin that started from the naturally 
occurring cephalosporin C and involved three biocatalytic transformations in fully 
aqueous medium [10, 11].  Finally, Du et al. and Wu et al. employed PGA in partially 
organic media to catalyze both the hydrolysis of penicillin G to the β-lactam nucleus 6-
APA and the enzymatic coupling of 6-APA with (R)-phenylglycine methyl ester ((R)-
PGME) or (R)-hydroxyphenylglycine methyl ester to synthesize ampicillin or 
amoxicillin, respectively, in a one-pot system [12, 13]. 
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 In this work, we examined the feasibility of utilizing a cascade conversion with 
two biocatalytic reactions in fully aqueous medium to synthesize ampicillin as shown in 
Figure 2.2.  In the first reaction, 6-APA was produced from the thermodynamically-
controlled hydrolysis of penicillin G with iPGA.  The by-product from this reaction, 
phenylacetic acid (PAA), is a known inhibitor of PGA with an inhibition constant equal 
to 70 µM [14].  In the second reaction, ampicillin was produced in a kinetically-
controlled coupling of 6-APA and (R)-PGME with either iPGA or AEH [15].   As AEHs 
are unique in their specificity toward α-amino groups on the acyl moiety, they cannot 
catalyze the hydrolysis of penicillin G to yield 6-APA and are not inhibited by PAA, thus 
their advantage in this cascade [16]. 
 We investigated both a one-pot, one-step (1P1S) and one-pot, two-step (1P2S) 
scheme.  In the 1P1S scheme, a batch process, we added (R)-PGME, penicillin G, and 
either iPGA or both iPGA and AEH at the beginning of the experiment.  In the 1P2S 
scheme, we first added penG with iPGA and allowed the reaction to proceed near 
completion to produce 6-APA.  Next, we added (R)-PGME and either AEH or additional 
iPGA to the reaction mixture.  We investigated the effect of different relative enzyme 


























































































Figure 2.2: One-pot, two-enzyme direct conversion of penicillin G (PENG) to ampicillin (AMP) using 
iPGA and AEH.  Undesired side reactions, primary hydrolysis of (R)-PGME and secondary hydrolysis of 
ampicillin, are shown. 
 




2.2 Materials and Methods 
2.2.1 Materials 
 6-Aminopenicillanic acid (6-APA), (R)-phenylglycine ((R)-PG), ampicillin, (R)-
phenylglycine methyl ester hydrochloride ((R)-PGME), penicillin G, phenylacetic acid 
(PAA), and Eupergit®-immobilized penicillin G acylase from Escherichia coli all were 
procured from Sigma Aldrich (St. Louis, MO, USA).  Soluble amino ester hydrolase 
from Xanthomonas campestris pv. campestris was prepared as described in Blum et al, 
2010 [15] . 
 
2.2.2 Ampicillin Synthesis with Immobilized Penicillin G Acylase 
 10 mL reactions with 20 mM 6-APA and 60 mM (R)-PGME in 100 mM 
phosphate buffer at pH 7 and room temperature (22oC-25oC) were carried out with 250 
mg iPGA, 124 UPenG per gram of carrier, where 1 UPenG is defined as one μmol of 
penicillin G hydrolyzed per minute.   
 
2.2.3 One-Pot, One-Step Synthesis 
 15 mL of 20 mM of penicillin G and 60 mM (R)-PGME in 100 mM phosphate 
buffer at pH 7 were added to a round bottom flask along with iPGA or iPGA and purified 
X. campestris pv. campestris AEH, per Table 2.1. The reactions were stirred using a 






2.2.4 One-Pot, Two-Step Synthesis 
 7.5 mL of 40 mM penicillin G in 100 mM phosphate buffer at pH 7 was added to 
a round bottom flask along with iPGA per Table 2.2, 124 UPenG per gram of carrier, 
where 1 UPenG is defined as one μmol of penicillin G hydrolyzed per minute.  The 
reactions were stirred using a magnetic stir plate and carried out at room temperature 
(22°C-25°C). After the reaction reached near completion, as determined by high 
performance liquid chromatography (HPLC), 7.5 mL of 120 mM (R)-PGME was added. 
The pH was adjusted with sodium hydroxide from ~6.4 to 7.0 and X. campestris pv. 
campestris AEH was added per Table 2.2, 79 UAmp per mg protein, where UAmp is 
defined as one μmol of ampicillin hydrolyzed per minute under saturation conditions. In 
reactions where iPGA was used in both steps, we replaced the AEH with equivalent 
ampicillin synthesis units of iPGA based on initial synthesis rate data from 6-APA and 
(R)-PGME using only AEH and only iPGA where 1 UAmp of AEH ≈ 1UAmp of iPGA ≈ 
6.8 UPenG of iPGA [15].   
 
2.2.5 One-Pot, Two-Step, Two-Stage Synthesis  
 These experiments were conducted analogously to the 1P2S schemes, with the 
exception that after the completion of the first step the iPGA was removed from the 
reaction using filtration. 
 
2.2.6 High Performance Liquid Chromatography Assay 
 All analysis was conducted using HPLC complete with a Shimadzu-LC-20AT 
pump, Beckman Coulter Ultrasphere ODS 4.6 mm x 25 cm column, and SPD-M20A 
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prominence diode array detector monitored at 215 nm. Samples were diluted 10X into 
HPLC quench buffer composed of 75% Methanol, 25% 0.02 M potassium phosphate, pH 
6.0. 2 μL of sample was loaded onto the column. The mobile phase operated under a 
gradient at 1.0 mL/min and contains 20% methanol and 80% 0.02 phosphate buffer at pH 
7 and increased to 50% methanol over a 25 min period. All components, (R)-PG, PAA, 
6-APA, (R)-PGME, ampicillin and penicillin G were detected using this method.  Results 
were normalized based on the penicillanic ring mass balance. More details on the HPLC 
method utilized can be found in Appendix B. 
 
2.3 Results and Discussion 
2.3.1 The Kinetically-Controlled Synthesis of Ampicillin 
 Shown in Figure 2.3 are characteristic concentration profiles for the components 
of the kinetically-controlled synthesis of ampicillin from 6-APA and (R)-PGME utilizing 
iPGA.  Figure 2.3 shows that ampicillin is initially produced via the synthesis reaction, 
achieves a maximum yield and then is completely consumed by secondary hydrolysis.  6-
APA is initially consumed by the synthesis reaction, its minimum concentration is 
achieved when ampicillin reaches its maximum yield, and then it is completely re-
generated by secondary hydrolysis.  (R)-phenylglycine ((R)-PG) is constantly produced 
by primary and secondary hydrolysis.  Finally, (R)-PGME is constantly being consumed 






Figure 2.3: Characteristic concentration profiles observed in the kinetically-controlled synthesis of 




2.3.2 One-Pot Synthesis of Ampicillin 
  We evaluated both the 1P1S and 1P2S systems over a range of iPGA and AEH 
concentrations as shown in Table 2.1 and Table 2.2.  In this cascade, enzyme 
concentrations have a large effect on the overall yield achieved and the degree of 
secondary hydrolysis observed.  Typical reaction profiles for both configurations are 
shown in Figure 2.4.   
 It has been previously shown that the initial ratio of 6-APA to (R)-PGME is an 
important parameter in optimizing the coupling reaction for semi-synthetic antibiotics 
[17].  In our experiments we used 20 mM 6-APA and 60 mM (R)-PGME which has been 
demonstrated as the optimal ratio for both iPGA and AEH-catalyzed syntheses [15].   
 
2.3.2.1 One-Pot, One-Step Synthesis 
 The two-enzyme 1P1S system resulted in ampicillin yields between 6% and 39%, 





















(R)-PG (R)-PGME 6-APA AMP
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enzyme loading (22 UPenG) and high AEH enzyme loading (11 UAmp).  AEHs have 
excellent (R)-PGME hydrolytic activity (kcat = 982 s-1) [15],  thus the majority of the (R)-
PGME was hydrolyzed prior to the production 6-APA that is necessary for synthesis. 
Increased iPGA enzyme loading (99 UPenG) and decreased AEH enzyme loading 
(between 1.1 UAmp – 5.5 UAmp) improved the ampicillin yields, with an optimum of 
39% yield when 99 UPenG iPGA and 4.4 UAmp AEH was utilized.   In the one-enzyme 
1P1S system with iPGA the reactions only achieved a maximum conversion of 10% after 
24 hours. The reduced reaction yield using iPGA alone was expected, due to the strong 
inhibition of iPGA with the intermediate PAA and the preference of iPGA for penicillin 










Moles of (R)-PGME per 
mole of AMP at max. 
(mol /mol) 
Maximum 






24.8 11 20 48 6 
99.2 1.1 360 8.7 23 
99.2 2.2 300 6.3 38 
99.2 4.4 60 7.5 39 
99.2 5.5 60 11 30 
99.2 none 360 31 3 
114 none 1500 21 10 
129 none 1500 20 9 
136 none 360 25 5 
[a] In ampicillin synthesis reactions starting from 6-APA and (R)-PGME, 1 UAmp of AEH 
≈ 6.8 UPenG of iPGA; [b] Time reported is the time that the maximum conversion was 
observed; [c] Conversions are based on the moles of ampicillin produced per moles of 
penicillin G starting material.  All concentrations are based on analytical measurements not 
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 To investigate the impact of the excess iPGA on the secondary hydrolysis in the 
system we conducted a one-pot, two-step, two-stage scheme where iPGA was removed 
by filtration prior to the addition of AEH to the system in the second step.  The removal 
of iPGA did not reduce the observed secondary hydrolysis of ampicillin, and therefore 
was not deemed beneficial to the 1P2S scheme.   
 The 1P1S system required fewer manipulations and has an overall faster cycle 
time but resulted in a lower overall yield when compared to the 1P2S system.  The lower 
observed yields are likely due to the lower initial 6-APA nucleophile concentrations as 6-
APA is generated at the same time it is consumed.   The 1P2S step system required 
higher cycle times but results in higher overall yields and allowed for the most control of 
the system parameters, including the 6-APA to (R)-PGME ratio, when compared to the 
1P1S system.    
 
2.4 Conclusions 
 The 1P1S scheme and the 1P2S scheme resulted in optimum ampicillin yields of 
39% and 47%, respectively.  In all cases, the two-enzyme system with iPGA and AEH 
out-performed the systems that used only iPGA, thus demonstrating the clear advantage 
of using AEH.  While the 1P1S system resulted in slightly lower yields, it could be 
advantageous due to its operational ease and faster cycle times.  In the 1P2S system, 
higher conversion was achieved and secondary hydrolysis was minimized by adjusting 
the relative enzyme loadings. These reaction schemes could be easily scaled up and 
incorporated with enzyme reuse, which has been previously demonstrated for iPGA[12, 
18].   
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2.5 Publication Information 
 The discussion of thermodynamic and kinetic syntheses of β-lactam antibiotics is 
published in Wiley’s Encyclopedia of Industrial Biotechnology (Ed. M.C. Flickenger, 
2010, pp 535-567) with Janna K. Blum and Andreas S. Bommarius as co-authors.  The 
research presented in Chapter 2 of this dissertation on the one-pot synthesis of ampicillin 
using AEH and PGA was published in ChemCatChem (Vol. 2, Issue 8, pp 987-991) with 
Janna K. Blum, Carolina V. Perez, and Andreas S. Bommarius as co-authors.  The date of 
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IMPROVING THE ENZYMATIC SYNTHESIS OF β-LACTAM ANTIBIOTICS 






 There are many advantages for enzymatic syntheses in organic solvents including 
increased solubilities of reactants and products, shifting reaction equilibria, and most 
importantly for the enzymatic coupling step in β-lactam antibiotic synthesis, suppressing 
hydrolysis reactions.  However, most enzymes show significantly decreased activity in 
organic co-solvents [1].  There have been numerous studies on the effects of different 
organic co-solvents on the synthesis of semi-synthetic β-lactam antibiotics [2-13].  Pan et 
al. studied the effect of the synthesis of ampicillin in fully organic media and attempted to 
correlate their results for yield with log P values.  They were able to obtain a yield of 
37.6% in ethyl acetate with a 24 hour reaction time and were not able to correlate their 
results with log P values [12].  van Langen et al. examined the synthesis of ampicillin in 
systems with less than 15% (v/v) water and found the more stable penicillin G acylase 
(PGA) from Alcaligenes faecalis to achieve 86% yield in 92% acetonitrile, though the 
beginning substrate concentrations were very low, 1 mM 6-aminopenicillanic acid and 3 
mM (R)-phenylglycine amide [7].  More commonly, the enzymatic synthesis of β-lactam 
antibiotics is studied in partially organic media.  Water miscible co-solvents, and more 
specifically polyols, are cited as suitable media for these syntheses [3, 4].  Ethylene 
glycol, methanol, 1,2-propanediol, 1,3-butanediol and glycerol, have all been reported to 
be advantageous for improving the synthesis of β-lactam antibiotics in terms of 
suppressing primary and secondary hydrolysis or improving yield [4, 6, 8, 9, 13].  Of 
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these co-solvents, ethylene glycol has been most studied because it has been proven be 
the most effective at improving the yield while maintaining productivity for β-lactam 
antibiotic syntheses.   
 Given the current state of the literature, we began our investigation into medium 
engineering by examining the effects of ethylene glycol on the kinetically-controlled 
synthesis of ampicillin from (R)-phenylglycine methyl ester ((R)-PGME) and 6-
aminopenicillanic acid (6-APA) catalyzed by penicillin G acylase (PGA).  Our initial 
studies revealed that an extra product is formed in synthesis reactions where ethylene 
glycol was employed as a solvent.  To our knowledge, this product has never been 
reported or studied.  The present work outlines how we identified the extra product as 
(R)-phenylglycine hydroxyethyl ester ((R)-PGHEE), why we hypothesized that the 
formation of (R)-PGHEE could be responsible for the yield enhancement observed in the 
synthesis of ampicillin from (R)-PGME and 6-APA with ethylene glycol as a co-solvent, 
how we characterized the PGA-mediated hydrolysis and ampicillin synthesis potential of 
(R)-PGHEE, and how we sought to find systems to act as positive and negative controls 
to test our  hypothesis.   
 
3.2 Materials and Methods 
3.2.1 Materials 
 6-aminopenicillanic acid (6-APA), (R)-phenylglycine ((R)-PG), ampicillin, (R)-
phenylglycine methyl ester hydrochloride ((R)-PGME), (R)-phenylglycine amide ((R)-
PGA), ethylene glycol, ethanol, tert-butyl alcohol, 2-nitro-5-[(phenylacetyl)amino]-
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benzoic acid (NIPAB), and Amberlyst® 15 were procured from Sigma Aldrich (St. 
Louis, MO, USA).   
 
3.2.2 Strains and Plasmids 
 The pac gene encoding penicillin G acylase has two mutations resulting in a 
LAla37Val substitution in the linker region and a βVal148Leu substitution in the mature 
protein as compared to the Swiss-Prot entry P06875 derived from E. coli ATC11105.   
 
3.2.3 Expression of Penicillin G Acylase 
 PGA was expressed in 500 mL cultures.  An overnight culture containing 5 mL 
LB media with 35 µg mL-1 chloramphenicol was inoculated from a single HB101 E. coli 
colony and grown overnight at 37oC with agitation at 300 RPM.  A 500 mL LB culture 
containing 35 µg mL-1 chloramphenicol was seeded from the overnight culture and 
grown at 37oC with agitation at 300 RPM to an OD600 of at least 0.8.  Subsequently, the 
expression culture was induced with 0.1 mM IPTG and incubated at 17oC and with 
agitation at 250 RPM for 18 hours.  After 18 hours, osmotic shock was performed by 
centrifugation at 3000 RPM (2280 x g) to obtain cell pellets; re-suspension of cell pellets 
in 5X volume of chilled osmotic shock buffer composed of 20% (w/v) sucrose, 100 mM 
TrisHCl and 10 mM EDTA at pH 8.0; centrifugation at 3000 RPM (2280 x g) to obtain 
cell pellets; re-suspension in 5X volume of chilled 1 mM EDTA to release the 





3.2.4 Ampicillin Synthesis Reactions  
 Periplasmic extract containing PGA was used for reactions containing varying 
concentrations of (R)-PGME and 6-APA per Tables 3.1; and varying concentrations of 
(R)-PGA and 6-APA per Table 3.2.  Reactions were performed in 100 mM phosphate 
buffer with varying volume percentages of ethylene glycol, ethanol, or tert-butyl alcohol.  
All reactions were at 25oC and pH 7.0, contained 37 µg of active PGA variant, and had a 
total volume of 1600 μL.  Reaction samples were taken at various points during the 
reaction and were quenched by diluting 10-fold with the addition of high performance 
liquid chromatography (HPLC) eluent for analysis with HPLC.   
 
3.2.5 High Performance Liquid Chromatography  
 HPLC analysis was completed with a Shimadzu-LC-20AT pump, Beckman 
Coulter Ultrasphere ODS 4.6 mm x 25 cm column, and SPD-M20A prominence diode 
array detector monitored at 215 nm. The mobile phase was isocratic at 1.0 mL min−1 with 
30% acetonitrile and 70% 5 mM phosphate buffer containing 300 mg L-1 sodium dodecyl 
sulfate at pH 2.65.  (R)-PG, 6-APA, ampicillin, (R)-PGA, (R)-PGHEE, and (R)-PGME 
were analyzed on the HPLC.  See Appendix B for more information on analytical 
methods [15]. 
 
3.2.6 Synthesis of (R)-Phenylglycine Hydroxyethyl Ester 
 (R)-Phenylglycine hydroxyethyl ester ((R)-PGHEE) was synthesized by reacting 
2 g of (R)-PGME with 15 mL of ethylene glycol at 120oC with the aid of 500 mg of 
Amberlyst® 15 catalyst until the reaction was near completion as assayed by HPLC.  The 
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product mixture was diluted with water to a volume of 50 mL, and extracted with 100 mL 
of 1 M potassium carbonate, followed by three extractions with 50 mL of 
dichloromethane.  Dichloromethane was removed by vacuum.  The product was 
identified by nuclear magnetic resonance, C10H13NO3, 1H NMR (acetone-d6): δ = 3.55 
(4H), δ = 4.10 (2H), δ = 4.60 (1H), δ = 7.34 (5H).  The resulting product was greater than 
90% pure as assayed by HPLC.  Hydrolysis reactions and ampicillin synthesis reactions 
with (R)-PGHEE were carried out at 25oC and pH 7. 
 
3.2.7 Chromogenic Activity Assay with 2-Nitro-5-[(Phenylacetyl)amino]-Benzoic Acid 
 2-Nitro-5-[(phenylacetyl)amino]-benzoic acid (NIPAB), a chromogenic substrate 
and a penicillin G analog, was used to determine the stability of PGA in various organic 
solvents.  PGA was incubated with different concentrations of organic co-solvents 
overnight and their residual activity on NIPAB was measured.  The hydrolysis of NIPAB 
liberates 5-amino-2-nitrobenzoic acid, which was monitored at 405 nm with a Beckmann-
Coulter DU®800 spectrophotometer.  NIPAB hydrolysis reactions were carried out at 
25oC in 50 mM phosphate buffer at pH 7.5 [16]. Detailed information for the NIPAB 
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3.3.1.2 Synthesis of Ampicillin from Varying Ratios of (R)-Phenylglycine Methyl Ester 
and 6-Aminopenicillanic Acid in Buffer and with Ethylene Glycol Co-Solvent 
 
 The synthesis of ampicillin in 0% (v/v) ethylene glycol and 30% (v/v) ethylene 
glycol was studied with nucleophile to electrophile ratios, or 6-APA to (R)-PGME ratios 
(6-APA:(R)-PGME), ranging from 0.33 to 3.0.  As shown in Figure 3.2A and Table 3.1, 
the highest yield in phosphate buffer is 38% and is achieved with 20 mM 6-APA and 60 
mM (R)-PGME, and the second best performing reaction achieves a yield of 34% with 60 
mM 6-APA and 20 mM (R)-PGME.  Interestingly, our results show that the yield 
achieved is highest for the lowest 6-APA:(R)-PGME when 6-APA:(R)-PGME is less 
than one, and is highest for the highest 6-APA:(R)-PGME when 6-APA:(R)-PGME is 
greater than one.  Results from reactions with a 6-APA:(R)-PGME equal to one, namely 
those that had 60 mM of each reactant or 45 mM of each reactant, achieved yields of 26% 
and 29%, respectively, and eliminate the possibility that the yields are simply enhanced 
by increasing the amount of total substrate.  These results suggest that two approaches 
can be taken to enhance the yields achieved in the kinetically-controlled synthesis of 
ampicillin in buffer.  First, an excess of nucleophile can be used to ensure that when an 
acyl-enzyme intermediate forms, a β-lactam nucleophile will be present to deacylate the 
enzyme resulting in a synthesis reaction.  The second approach, which is more effective, 
is to use an excess of the electrophile acyl side chain donor to compensate for the acyl 
donor that is lost to hydrolysis.  The advantageous choice to use an excess of acyl donor 
is further supported by the facts that the hydrolysis product, (R)-phenylglycine ((R)-PG), 
can be recycled, and that 6-APA has limited stability and should be converted as much as 
possible in one pass [17].  
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 As shown in Figure 3.2B and Table 3.1, the highest yield in 30% (v/v) ethylene 
glycol is 45% and is achieved with 20 mM 6-APA and 60 mM (R)-PGME, which equates 
to a 7 percentage point yield improvement as compared to the reaction performed in 
buffer with the same 6-APA:(R)-PGME.  In contrast to the reactions in buffer, the second 
highest yielding reaction is achieved with 20 mM 6-APA and 45 mM (R)-PGME.  A 
closer examination of the data shows that the difference in trends observed with 6-
APA:(R)-PGME and yield in 0% (v/v) and 30% (v/v) ethylene glycol results from a 
variation in the benefit of utilizing ethylene glycol as a co-solvent with 6-APA:(R)-
PGME as shown in Table 3.1.  Specifically, the increase in percent yield observed for 
ampicillin synthesis performed with an ethylene glycol co-solvent was found to increase 
with the amount of (R)-PGME present in the reaction, while the increase in percent yield 
was found to be minimal, less than a three percentage points, for all reactions where 6-
APA was in excess.   
 
 
Table 3.1 Ampicillin synthesis with varying 6-APA:(R)-PGME in 0% (v/v) ethylene glycol, and in 30% 
(v/v) ethylene glycol 
6-APA:(R)-PGME Concentration (mM) Maximum Yield (%) Δ Yield (% points) 





0.33 20 60 38 45 7 
0.44 20 45 30 35 5 
0.61 20 33 23 27 4 
1.00 20 20 17 18 1 
1.65 33 20 22 24 2 
2.25 45 20 27 29 2 
3.00 60 20 34 34 1 
1.00 45 45 26 29 3 










-PGME in A) 
ne glycol 
0% (v/v) ethylene glycol, and in  
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3.3.1.3 Discovery of Intermediate Formed in Synthesis of Ampicillin from (R)-
Phenylglycine Methyl Ester and 6-Aminopenicillanic Acid with Ethylene Glycol Co-
Solvent 
 
 HPLC analysis showed an extra product forming in reactions where ethylene 
glycol was employed as a co-solvent.  We hypothesized that the compound that is formed 
is the transesterification product of (R)-PGME and ethylene glycol, (R)-PGHEE, based 
on the following three observations: (1) the amount of product increased with the amount 
of (R)-PGME in the reaction, (2) the amount of product increased with the amount of 
ethylene glycol in the reaction, and (3) the product was present in systems containing 
only (R)-PGME and ethylene glycol but was not present in systems containing only 6-
APA and ethylene glycol.  (R)-PGME hydrolysis reactions in 0% (v/v) ethylene glycol 
and in 30% (v/v) ethylene glycol with and without the presence of PGA indicate that the 
formation of this product is not dependent on an enzymatic reaction, or that its 
enzymatically-catalyzed hydrolysis is much faster than the enzymatically-catalyzed 
synthesis.  Interestingly, in the absence of PGA (R)-PGME is consumed at the same rate 











 To our knowledge the formation of this product or its effect on the synthesis of 
ampicillin has never been reported.  The concentration of the product is transient, 
indicating that it is formed and consumed during the course of the reactions.  Since the 
specificity of PGA is limited to the phenylacetyl portion of its substrates, if the product 
formed in reactions containing ethylene glycol as a co-solvent is (R)-PGHEE, it could be 
employed by the enzyme to synthesize ampicillin.  Thus, we hypothesized that the 
formation of (R)-PGHEE is contributing to the yield enhancement observed in the 
synthesis of ampicillin from (R)-PGME and 6-APA employing ethylene glycol as a co-
solvent, based on the observations that: (1) the loss of acyl donor in the reaction affects 
the overall yield achieved, (2) the yield enhancement observed for the synthesis of 
ampicillin is dependent on the amount of (R)-PGME used for the synthesis reaction, (3) 
the most widely-reported type of co-solvent cited in the literature for ampicillin synthesis 
are polyols, which are all theoretically capable of transesterification of (R)-PGME, and 
(4) all instances reported in the literature for the improved synthesis of a β-lactam 
antibiotic as a result of the use of a polyol co-solvent have used an excess of (R)-PGME.  
Essentially, transesterification of (R)-PGME to (R)-PGHEE rather than hydrolysis of (R)-
PGME to (R)-PG would re-direct the consumption of (R)-PGME to an intermediate that 
could be used to synthesize ampicillin, rather than to an unusable hydrolysis side product.  
The resulting system would represent an in-situ mixed donor synthesis, where both (R)-
PGME and (R)-PGHEE act as side chain acyl donors to synthesize ampicillin as shown in 
Figure 3.3.  A mixed donor synthesis from (R)-phenylglycine amide ((R)-PGA) and (R)-
PGME has been reported previously as an ex-situ means to improve the rate of ampicillin 
54 
 
synthesis while maintaining equivalent yields and recycling the hydrolysis product (R)-
PG [18].   
 
3.3.2 Synthesis of Ampicillin from (R)-Phenylglycine Amide and 6-Aminopenicillanic 
Acid with Ethylene Glycol Co-Solvent 
 
 (R)-phenylglycine amide ((R)-PGA) is an alternative acyl side chain donor to (R)-
PGME that can be used to synthesize ampicillin.  The suppression of primary and 
secondary hydrolysis reactions is present in reactions with (R)-PGA when ethylene 
glycol is employed as a co-solvent, but (R)-PGA is more stable than (R)-PGME and we 
have found that it does not undergo transesterification with ethylene glycol.   Therefore, 
the synthesis of ampicillin from (R)-PGA and 6-APA in 30% (v/v) ethylene glycol acts a 
negative control for the hypothesis that the formation of (R)-PGHEE is contributing to 




Table 3.2 Ampicillin synthesis with varying 6-APA:(R)-PGA in 0% (v/v) ethylene glycol, and in 30% (v/v) 
ethylene glycol 
6-APA:(R)-PGA Concentration (mM) Maximum Yield (%) Δ Yield (% points) 
  6-APA (R)-PGA 
0% (v/v) 
 Ethylene Glycol 
30% (v/v) 
Ethylene Glycol 
0.33 20 60 34 34 0 
0.44 20 45 24 23 -1 
0.61 20 33 17 19 2 
1.00 20 20 10 13 3 
1.65 33 20 18 19 1 
2.25 45 20 20 23 3 
3.00 60 20 27 30 3 
1.00 45 45 21 23 2 















ene glycol, and in  
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 To study the effects of the synthesis of ampicillin without the presence of (R)-
PGHEE, the synthesis of ampicillin in 0% (v/v) ethylene glycol and 30% (v/v) ethylene 
glycol was studied with ratios of 6-APA to (R)-PGA (6-APA:(R)-PGA) ranging from 
0.33 to 3.0.  Figure 3.4A and Table 3.2 show that the trends in yield achieved with 
varying 6-APA:(R)-PGA in buffer are consistent with those observed for 6-APA:(R)-
PGME.  The best performing 6-APA:(R)-PGA was 20 mM 6-APA and 60 mM (R)-PGA  
which achieved a yield of 34%, followed by the reaction containing 60 mM 6-APA and 
20 mM (R)-PGME which achieved a yield of 27%.  Again, it was observed that the yield 
is highest the further the nucleophile to electrophile ratio is from unity.  These results 
further support the finding that either an excess of nucleophile or an excess of 
electrophile should be used in the kinetically-controlled synthesis of ampicillin.   
 Interestingly, the trend observed with varying 6-APA:(R)-PGA in 30% (v/v) 
ethylene glycol is identical to that observed for 6-APA:(R)-PGA in buffer and 6-
APA:(R)-PGME in buffer as shown in Figure 3.4B and Table 3.2.  Furthermore, it was 
determined that the effect of using an ethylene glycol co-solvent only minimally 
increased the yield achieved, less than three percentage points, for all 6-APA:(R)-PGA 
studied.   
 
3.3.3 Comparison of Ampicillin Synthesis from Different Activated Acyl Donors in Buffer 
and with Ethylene Glycol Co-Solvent 
 
 To compare the syntheses with different activated acyl donors and the syntheses 
with and without employing ethylene glycol as a co-solvent, we will compare the four 
reactions that had a nucleophile to electrophile ratio of 0.33 as they led to the highest 
yielding reaction in all four sets of synthesis reactions studied.  The initial rates of (R)-PG 
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generation, ampicillin generation, and (R)-PGME or (R)-PGA consumption for these four 
reactions can be found in Table 3.3. 
 Utilizing (R)-PGME as an activated acyl side chain donor leads to faster initial 
rates of synthesis and higher yields of ampicillin in comparison to using (R)-PGA for all 
of the nucleophile to electrophile concentrations studied in this work.  In buffer, the 
synthesis with 20 mM 6-APA and 60 mM electrophile results in a 1.2-fold increase in the 
initial rate of synthesis and a maximum yield that is four percentage points greater when 
(R)-PGME is employed as opposed to (R)-PGA.  In 30% (v/v) ethylene glycol, the 
synthesis with 20 mM 6-APA and 60 mM electrophile results in a 1.2-fold increase in the 
initial rate of synthesis and a maximum yield 11 percentage points greater when (R)-
PGME is used as opposed to (R)-PGA.  When (R)-PGME is the activated acyl side donor 
of choice, the initial rates of (R)-PG generation, ampicillin synthesis, and (R)-PGME 
consumption in 30% (v/v) ethylene glycol are 20%, 30%, and 41%, respectively, of the 
rates observed in buffer.  Therefore, the rate of primary hydrolysis is suppressed to a 
greater extent than the rate of synthesis, which in combination with suppressed secondary 
hydrolysis, leads to the observed yield increase.  When (R)-PGA is the activated acyl side 
donor of choice, the initial rates of (R)-PG generation, ampicillin synthesis, and (R)-PGA 
consumption in 30% (v/v) ethylene glycol are 28%, 27%, and 31%, respectively, of the 
rates observed in buffer.  Therefore, in the reactions with (R)-PGA all reactions are 
impeded by the presence of ethylene glycol to an equal extent and therefore an 




 The PGA-catalyzed hydrolysis of 20 mM ampicillin was carried out to study the 
effect of ethylene glycol on the secondary hydrolysis reaction.  The rate of ampicillin 
hydrolysis in 30% (v/v) ethylene glycol was found to be 26% of the rate in buffer, 
explaining the significant decrease in secondary hydrolysis for all reactions where 
ethylene glycol was employed as a co-solvent as shown in Figures 3.2 and 3.4.     
 
 
Table 3.3 Synthesis of ampicillin from 20 mM 6-APA and 60 mM side chain acyl donor in 0% (v/v) 
ethylene glycol and 30% (v/v) ethylene glycol. 
 Medium (R)-PG Generation Ampicillin Generation Acyl Donor Consumption 
  (mM min-1) (mM min-1) (mM min-1) 
Ampicillin Synthesis from (R)-PGME 
0% (v/v) ethylene glycol 0.325 0.256 0.616 
30% (v/v) ethylene glycol 0.070 0.078 0.257 
Ampicillin Synthesis from (R)-PGA 
0% (v/v) ethylene glycol 0.269 0.236 0.469 




3.3.4 Synthesis of Ampicillin from (R)-Phenylglycine Methyl Ester and 6-
Aminopenicillanic Acid with Ethanol and tert-Butyl Alcohol Co-Solvents 
 
 To probe the extent to which transesterification of (R)-PGME by a co-solvent 
positively affects yield, the synthesis of ampicillin in other co-solvents bearing an alcohol 
group was investigated.  Finding such a co-solvent would serve as a positive control to 
the reactions with an ethylene glycol co-solvent where (R)-PGHEE is present and the 
yield is positively affected.  We limited our studies to ethanol and tert-butyl alcohol 






3.3.4.1 Synthesis of Ampicillin from (R)-Phenylglycine Methyl Ester and 6-
Aminopenicillanic Acid with Ethanol Co-Solvent 
 
 The synthesis of ampicillin from 20 mM 6-APA and 60 mM (R)-PGME was 
investigated in amounts of ethanol ranging from 0% (v/v) to 40% (v/v).  PGA was shown 
to retain 93% and 60% of its activity on NIPAB after overnight incubation with 20% 
(v/v) and 40% (v/v) ethanol, respectively.  We found that the transesterification product 
of ethanol and (R)-PGME, (R)-phenylglycine ethyl ester ((R)-PGEE), was produced in 
reactions in 20% (v/v) and 40% (v/v) ethanol.  However, the decrease in the rate of 
ampicillin synthesis in ethanol is drastic, only 6% of the initial synthetic activity is 
observed in 20% (v/v) ethanol as compared to buffer.  As a result, the maximum yield 
achieved in 20% (v/v) or 40% (v/v) ethanol was lower than that observed in buffer, only 
28.5% and 12.9%, respectively, after 12 hours.  The initial rate in 10% (v/v) ethanol was 
33% of that observed in buffer, but the maximum yield achieved was only 38.9%, 
representing a less than 1% yield enhancement as compared to reaction in buffer.  
Furthermore, an insignificant amount of (R)-PGEE was produced in 10% (v/v) ethanol.  
Because the transesterification of (R)-PGME was only present at ethanol concentrations 
that severely impeded the rate of ampicillin synthesis and maximum yield achieved, we 
determined that utilizing the co-solvent ethanol would not serve to prove or disprove that 
the transesterification by a co-solvent positively affect yield.  
 
3.3.4.2 Synthesis of Ampicillin from (R)-Phenylglycine Methyl Ester and 6-
Aminopenicillanic Acid with tert-Butyl Alcohol Co-Solvent 
 
 The synthesis of ampicillin from 20 mM 6-APA and 60 mM (R)-PGME was 
investigated in amounts of tert-butyl alcohol ranging from 0% (v/v) to 30% (v/v).  
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However, tert-butyl alcohol was also found to severely impede PGA’s synthetic activity 
for ampicillin synthesis.  The rate of ampicillin synthesis was found to be only 21% and 
11% of the rate observed in buffer for 10% (v/v) and 20% (v/v) tert-butyl alcohol, 
respectively, and the resulting yields were only 22% and 11%, respectively.   
Furthermore, we were not able to identify the formation of (R)-phenylgyine tert-butyl 
ester, the transesterification product between (R)-PGME and tert-butyl alcohol.  These 
results indicate that tert-butyl alcohol also cannot serve as a co-solvent to prove or 
disprove that the transesterification of (R)-PGME by a co-solvent can positively affect 
yield in the synthesis of ampicillin.  
 
3.3.5 Penicillin G Acylase’s Activity for (R)-Phenylglycine Hydroxyethyl Ester  
3.3.5.1 Hydrolysis of (R)-Phenylglycine Hydroxyethyl Ester 
 The chemical and enzymatic hydrolysis of 60 mM (R)-PGHEE was investigated.  
We found the PGA-catalyzed rate of (R)-PGHEE hydrolysis to be 0.085 mM min-1, 
which is 20% and 27% of the rate of the enzymatic hydrolysis of (R)-PGME and (R)-
PGA, respectively.  The rate of chemical hydrolysis rate of (R)-PGHEE was determined 
to be 0.056 mM min-1, surprisingly high at 66% of the total hydrolysis rate of (R)-
PGHEE in the presence of PGA.  For comparison, the rate of background hydrolysis of 
(R)-PGME is 13% of the rate of combined chemical and enzymatic hydrolysis, and the 
chemical hydrolysis of (R)-PGA does not occur at all under the reaction conditions and 







3.3.5.2 Synthesis of Ampicillin from (R)-Phenylglycine Hydroxyethyl Ester and 6- 
Aminopenicillanic Acid 
 
 (R)-PGHEE was tested for its ability to synthesize ampicillin with 6-APA.  (R)-
PGHEE was found to be a viable acyl side side chain donor for ampicillin synthesis. 
However, the rate of synthesis from 20 mM 6-APA and 60 mM (R)-PGHEE was only 
0.013 mM min-1, which is about 5% of the synthesis rates observed for (R)-PGME and 
(R)-PGA.  This result is astounding given the fact that Bristol-Myers Squibb (Princeton, 
NJ, USA) has previously reported that ethylene glycol esters are its most preferred form 
of activated acyl side chain donors [19].   
 
3.4 Conclusions 
 In this work, we have investigated the kinetically-controlled synthesis of 
ampicillin with different activated acyl side chain donors in partially organic media.  We 
have found that utilizing ethylene glycol as a co-solvent decreases the rates of primary 
and secondary hydrolysis observed in the kinetically-controlled synthesis of ampicillin.  
We have found that the primary hydrolysis observed in the synthesis from (R)-PGME is 
suppressed to a lesser extent than the primary hydrolysis observed in the synthesis from 
(R)-PGA.  The suppression of secondary hydrolysis of ampicillin in the presence of 
ethylene glycol is equivalent for both reactions.   
 Furthermore, we have investigated the effect that transesterification by a co-
solvent has on the yield enhancement observed in the synthesis of ampicillin.  We have 
confirmed that ethylene glycol transesterifies (R)-PGME to intermittently produce (R)-
PGHEE but does not transesterify (R)-PGA.  Therefore, ampicillin synthesis with (R)-
PGA in the presence of 30% (v/v) ethylene glycol represent a system that has suppressed 
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hydrolysis reactions in the absence of transesterification by a co-solvent.  When (R)-PGA 
is used at the activated acyl side chain, we have found that the use of ethylene glycol as a 
co-solvent has minimal effects on the yield of ampicillin achieved, in all cases less than 
three percentage points.  When (R)-PGME is used as the activated acyl side chain, we 
have found that yield enhancement observed when employing ethylene glycol as a co-
solvent is dependent on the amount of (R)-PGME present.   
 Also, we have demonstrated that (R)-PGHEE is capable of acting as a side chain 
acyl donor to synthesize ampicillin.  Based on our results, there is evidence that the 
synthesis of ampicillin from (R)-PGME and 6-APA with an ethylene glycol co-solvent 
acts as an in situ mixed donor synthesis, where both (R)-PGME and (R)-PGHEE are acyl 
side chain donors for the synthesis of ampicillin, and that the mixed donor synthesis 
contributes to the enhanced yield observed.   
 
3.5 Publication Information 
 The research presented in Chapter 3 of this dissertation will be submitted to 
Chemical Communications by August 10th, 2011 for publication with Andreas S. 
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IMPROVING THE ENZYMATIC SYNTHESIS OF β-LACTAM ANTIBIOTICS 





 Stereoselective processes for preparation of pharmaceuticals is especially 
important as stereoisomers often have different pharmacokinetic, pharmacologic, and 
toxicologic effects [1].  However, penicillin G acylase (PGA) exhibits relaxed 
diastereoselectivity and therefore enantiomerically pure acyl donor substrates must be 
prepared for the enzymatic synthesis of semi-synthetic β-lactam antibiotics.  In this study, 
we aimed to use protein engineering to improve the selectivity of PGA with respect to the 
amino group on the alpha carbon (Cα) in the synthesis of ampicillin from rac-
phenylglycine methyl ester (rac-PGME) and 6-aminopenicillanic acid (6-APA) so that 






































Figure 4.1: The synthesis of ampicillin from rac-PGME.  Primary hydrolysis of rac-PGME and secondary 




 Currently, when starting with rac-PGME and 6-APA, PGA will catalyze the 
synthesis of the desired product, (R)-ampicillin, in addition to an undesired product, (S)-
ampicillin, as shown in Figure 4.1.   PGA shows an initial diastereomeric excess (d.e.) of 
15% and a d.e. value of 37% at the point when the maximum yield of (R)-ampicillin is 
achieved, both with respect to the desired synthesis product, (R)-ampicillin.  Morley and 
Kazlauskas found that mutations close to the active site are most effective in altering 
enzyme selectivity [2]. Therefore to alter the selectivity of PGA we targeted residues 
based their proximity to the Cα of the inhibitor penicillin G sulfoxide for site-saturation 
with NNK libraries (N represents and equal mixture of the nucleotide bases A, G, C, and 
T; and K represents an equal mixture of T and G).  Residues that are known to be 
necessary for catalysis were not considered for mutation.  The five residues that are 
within 6 Å of the Cα penicillin G sulfoxide and therefore were chosen to study for 
diasteromer selectivity improvement are αPhe146, βPro22, βPhe24, βThr68, and βPhe71 
(the amino acid residues are labeled to indicate the chain, α or β, the wild type amino acid 
residue, the reside number on the chain, and the variant amino acid residue when 
applicable).  Figure 4.2 shows the residues chosen for mutation in the active site of PGA 
Though little research has been completed on the selectivity of PGA with respect to the 
substituent on the Cα, extensive research on the first shell residues in the active site of 
PGA has been completed.  Previous alignment of eight known class IIa PGA sequences 
shows that in comparison to the wild-type residues of PGA from E. coli, αPhe146 is 
37.5% conserved, βPro22 is 100% conserved, βPhe24 is 75% conserved, βThr68 is 100% 
conserved, and βPhe71 is 62.5% conserved [3].  Residue αPhe146 is known to act as a 
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 Only two studies on the selectivity of PGA with respect to substituents on Cα 
position have been completed.  Švedas, et al. completed an extensive study on the 
substrate specificity of wild-type PGA and found that PGA did not have any significant 
stereospecificity for substrates with the polar groups –OH or –NH2 at the Cα position [8].  
Alkema et al. studied the selectivity of wild-type PGA and the PGA variants βPhe24Ala, 
αPhe146Tyr, and the double variant βPhe24Ala/αPhe146Tyr with various Cα-substituted 
substrates, though the selectivity with an amino group substituent was not studied.  The 
selectivity of wild-type PGA was found to be dependent on the size and polarity of the 
substituent, PGA variant βPhe24Ala was found to increase enantioselectivity towards all 
(R)-enantiomers, variant αPhe146Tyr was shown to have enantioselectivity similar to the 
wild-type, and double variant βPhe24Ala/αPhe146Tyr was shown to have additive 
enantioselective properties of the two single point mutations [7].  Both studies 
investigated the enantioselectivity of PGA by utilizing enantiomeric substrates as 
inhibitors, experimentally determining their inhibition constants, and comparing them to 
determine the enzyme’s enantioselectivity. 
 To our knowledge, the present work is the first study to investigate and improve 
the selectivity of PGA with respect to substrates’ Cα with site-saturation of individual 
residues.  Furthermore, this research represents the first time that the selectivity of PGA 
with respect to the Cα has been investigated for a synthesis reaction to produce a 






4.2 Materials and Methods 
4.2.1 Materials 
 6-aminopenicillanic acid (6-APA), (R)-phenylglycine ((R)-PG), ampicillin, (R)-
phenylglycine methyl ester hydrochloride ((R)-PGME), (S)-phenylglycine methyl ester 
hydrochloride ((S)-PGME), phenylmethylsulfonyl fluoride (PMSF), and 2-nitro-5-
[(phenylacetyl)amino]-benzoic acid (NIPAB) were procured from Sigma Aldrich (St. 
Louis, MO, USA).   
 
4.2.2 Strains and Plasmids 
 The pac gene encoding penicillin acylase has two mutations resulting in a 
LAla37Val substitution in the linker region and a βVal148Leu substitution in the mature 
protein as compared to the Swiss-Prot entry P06875 derived from E. coli ATC11105.   
 
4.2.3 Mutagenesis  
 Diverse libraries were generated by following the protocol of QuikChangeTM Site-
Directed Mutagenesis Kit.  The forward and reverse primers utilized to create the 
αPhe146 library were 5’-GC ACC ATG GCA AAC CGC NNK TCG GAT AGC ACT 
AGC GAA ATC G-3’ and 5’-C GAT TTC GCT AGT GCT ATC CGA MNN GCG GTT 
TGC CAT GGT GC-3’, respectively.  The forward and reverse primers utilized to create 
the βPro22 library were 5’-CG AAA GCA ATC ATG GTA AAT GGT NNK CAA TTT 
GGC TGG TAT GCG C-3’ and 5’-G CGC ATA CCA GCC AAA TTG MNN ACC ATT 
TAC CAT GAT TGC TTT CG-3’, respectively.  The forward and reverse primers 
utilized to create the βPhe24 library were 5’-CA ATC ATG GTA AAT GGT CCG CAG 
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NNK GGT TGG TAT GCG CCT GCG-3’ and 5’-CGC AGG CGC ATA CCA ACC 
MNN CTG CGG ACC ATT TAC CAT GAT TG-3’, respectively.  The forward and 
reverse primers utilized to create the βThr68 library were 5’-GGT GTG ATT TCC TGG 
GGA TCA NNK GCT GGT TTC GGC GAT GAT G-3’ and 5’-C ATC ATC GCC GAA 
ACC AGC MNN TGA TCC CCA GGA AAT CAC ACC-3’, respectively.  The forward 
and reverse primers utilized to create the βPhe71 library were 5’-C TGG GGA TCA 
ACG GCA GGT NNK GGT GAT GAT GTC GAT ATT TTT GCT G-3’ and 5’-C AGC 
AAA AAT ATC GAC ATC ATC ACC MNN ACC TGC CGT TGA TCC CCA G-3’, 
respectively.  The point mutation βPhe24Ala was also generated by following the 
protocol of QuikChangeTM Site-Directed Mutagenesis Kit.  The forward and reverse 
primers utilized to create the βPhe24Ala were 5’-CA ATC ATG GTA AAT GGT CCG 
CAG GCG GGT TGG TAT GCG CCT GCG-3’ and 5’-CGC AGG CGC ATA CCA 
ACC CGC CTG CGG ACC ATT TAC CAT GAT TG-3’, respectively.  The resulting 
PCR products were transformed into competent XL1-Blue E. coli cells and grown 
overnight in LB media containing 35 μg mL-1 chloramphenicol at 37oC.  Liquid cultures 
were subsequently mini-prepped, transformed into competent HB101 E. coli cells, and 
grown overnight on agar plates containing 35 μg mL-1 chloramphenicol.  Library 
diversity was confirmed with sequencing.  
  
4.2.4 Expression of Penicillin G Acylase and Penicillin G Acylase Variants 
 Libraries of PGA variants were expressed in 96-well microtiter plates.  Master 96-
well microtiter plates containing 170 µL LB media with 35 µg mL-1 chloramphenicol 
were inoculated from single HB101 E. coli colonies and grown overnight at 37oC with 
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agitation at 180 RPM.  Expression plates were created by replicate plating of 
transformants into 170 µL LB media with 35 µg mL-1 chloramphenicol and grown at 
37oC with agitation at 180 RPM for 8 hours.  After 8 hours, expression plates were 
induced with 0.1 mM IPTG and incubated at 17oC and with agitation at 180 RPM for 18 
hours.  After 18 hours, osmotic shock was performed in 96-well microtiter plates by 
centrifugation at 1500 RPM (1230 x g) to obtain cell pellets; re-suspension of cell pellets 
in 5X volume of chilled osmotic shock buffer composed of 20% (w/v) sucrose, 100 mM 
TrisHCl and 10 mM EDTA at pH 8.0; centrifugation at 1500 RPM (1230 x g) to obtain 
cell pellets; re-suspension in 5X volume of chilled 1 mM EDTA to release the 
periplasmic fraction; and centrifugation at 1500 RPM (1230 x g) to pellet cell debris.  
Master plates were stored at -80oC after addition of 50 µL of 70% sterile glycerol.  Large-
scale expression and osmotic shock to obtain periplasmic extracts of library hits was 
completed as described in Chapter 3.   
 
4.2.5 Ampicillin Synthesis Reactions with Racemic and Pure Substrates 
 Periplasmic extracts obtained from 96-well microtiter expression plates were 
utilized in reactions containing 90 mM rac-PGME and 20 mM 6-APA in 100 mM 
phosphate buffer to complete the library screening.  Reactions were started by the 
addition of 50 μL of substrate mixture at 25oC and pH 7.0 to 10 μL of periplasmic extract 
containing PGA variants in 96-well microtiter plates.  After 6 hours the reactions were 
sampled and quenched by diluting 10-fold with the addition of HPLC eluent for analysis 
with HPLC.  Library hits were expressed on a large-scale and their periplasmic extracts 
were used for reactions containing 90 mM rac-PGME and 20 mM 6-APA; 60 mM (R)-
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phenylglycine methyl ester and 20 mM 6-APA; and 60 mM (S)-phenylglycine methyl 
ester and 20 mM 6-APA.  All larger scale reactions were in 100 mM phosphate buffer, at 
25oC and pH 7.0, contained 37 µg of active PGA variant, and had a total volume of 1600 
μL.  Reaction samples were taken at various points during the reaction and were 
quenched by diluting 10-fold with the addition of HPLC eluent for analysis with HPLC.   
 
4.2.6 High Performance Liquid Chromatography  
 High-performance liquid chromatography (HPLC) analysis was completed with a 
Shimadzu-LC-20AT pump, Beckman Coulter Ultrasphere ODS 4.6 mm x 25 cm column, 
and SPD-M20A prominence diode array detector monitored at 215 nm. The mobile phase 
was isocratic at 1.0 mL min−1 that initially contained 12.5% methanol and 87.5% 20 mM 
phosphate buffer at pH 7.0, increased via a step change to 30.0% methanol and 70% 20 
mM phosphate buffer at pH 7.0 after 7 minutes, and decreased via a step change to 12.5% 
methanol and 87.5% 20 mM phosphate buffer at pH 7.0 after 30 min until 40 min. 
Phenylglycine, 6-APA, (R)-ampicillin, and (S)-ampicillin were analyzed on the HPLC. 
(R)-ampicillin and (S)-ampicillin diastereomers separate on the HPLC, however, the 
enantiomers of (R)-phenylglycine and (S)-phenylglycine; and (R)-phenylglycine methyl 
ester and (S)-phenylglycine methyl ester co-eluted with the stated method.  See Appendix 
B for more information on analytical methods. 
 
4.2.7 Chromogenic Activity Assay with 2-Nitro-5-[(Phenylacetyl)amino]-Benzoic Acid 
 2-Nitro-5-[(phenylacetyl)amino]-benzoic acid (NIPAB), a chromogenic substrate 
and a penicillin G analog, was employed in order to determine the hydrolysis activity of 
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the PGA variants.  The hydrolysis of NIPAB liberates 5-amino-2-nitrobenzoic acid, 
which was monitored at 405 nm with a Beckmann-Coulter DU®800 spectrophotometer.  
NIPAB hydrolysis reactions were carried out at 25oC in 50 mM phosphate buffer at pH 
7.5 [9]. Detailed information for the NIPAB assay, along with other analytical techniques 
can be found in Appendix B.  
 
4.2.8 Active Site Titration with Phenylmethylsulfonyl Fluoride 
 The amount of active PGA was determined by duplicate active site titrations with 
the irreversible inhibitor phenylmethylsulfonyl fluoride (PMSF).  Wild-type PGA and 
PGA variants were incubated with varying concentrations of PMSF for at least 10 
minutes and residual activity on NIPAB was measured.  Varying concentrations of PMSF 
were prepared for immediate use by diluting a 10 mM stock solution of PMSF in 
acetonitrile with 50 mM phosphate buffer at pH 7.5 [9].   
 
4.3 Results and Discussion 
4.3.1 Screening for Mutants with Improved Selectivity 
 Diverse NNK libraries were screened by comparing the ratio of the production of 
(R)-ampicillin to (S)-ampicillin for PGA variants to that of the wild-type PGA in the 
synthesis of ampicillin from rac-PGME and 6-APA in 96-well microtiter plates.  PGA 
libraries targeting improvements in the synthesis of semi-synthetic β-lactam antibiotics 
are typically difficult to screen due to the combination of varying expression and activity 
levels among variants, and to the transient nature of antibiotic formation observed in 
synthesis reactions.  As a result, it is often difficult to determine an appropriate sampling 
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time when screening PGA variants for improved synthesis properties.  However, these 
difficulties are all but eliminated when screening variants for improved selectivity, as 
selectivity at an early point in the reaction is typically indicative of the selectivity 
observed during the course of the reaction.  Furthermore, screening for improved mutants 
with the desired synthesis reaction, rather that selecting for active mutants with the 
widely-employed auxotrophic hydrolysis based assay with D-phenylglycyl-L-leucine, 
proved to be necessary for this study, as the majority of our improved variants showed 
significantly decreased hydrolysis activity.   
 We screened at least 94 PGA variants which results in greater than 95% library 
coverage for each NNK library.  Of all the PGA variants screened, 23% were active 
variants and 76% were inactive variants, agreeing with what is expected when making 
mutations around the active site of PGA [10].  PGA is expressed as a single cytoplasmic 
precursor and must undergo autocatalytic processing to render an active enzyme.  The 
residues in the active site of PGA are notoriously difficult to mutate due to their 
participation in precursor processing [11].  Of the active variants, 14% had improved 
selectivity towards (R)-ampicillin synthesis and 59% had improved selectivity for (S)-
ampicillin synthesis, though many of the variants showed low activity or poor expression.  
The remaining active variants did not show a significant change in diastereomer 
selectivity.  As we are ultimately interested in obtaining an (R)-selective PGA, all 
variants that showed improvement towards (R)-ampicillin selectivity were sequenced.  
Additionally, the top 25 variants that showed improvement towards (S)-ampicillin 
selectivity were sequenced.   
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 Overall, sequencing revealed thirteen non-duplicitous variants from our library 
screening as potentially interesting mutants for improving the selectivity of PGA.  Three 
variants showed improvement towards (R)-ampicillin synthesis and 10 variants showed 
improvements for (S)-ampicillin synthesis, as assayed by our 96-well microtiter plate 
screening reactions.  βPhe24Ala was not identified from library screening, but was 
targeted for mutagenesis due to the fact that it was previously shown to be selective for 
(R)-enantiomers with substituents other than an amino group at the Cα position [7].  This 
point mutation proved to be very difficult to obtain which is likely why it was not 
captured during the library screening.  All fourteen variants were expressed on a large-
scale and the purities of their periplasmic extracts were determined with duplicate 
phenylmethylsulfonyl fluoride (PMSF) titrations.  The purities of periplasmic extracts for 
the PGA variant ranged from 10% to 25% and were confirmed with SDS-PAGE analysis. 
Subsequently, large-scale ampicillin synthesis reactions with rac-PGME were completed 
in order to confirm the selective behavior of the PGA variants observed in the 96-well 
microtiter plate screen.  
 
4.3.2 Ampicillin Synthesis from Racemic Substrates 
 Large-scale synthesis reactions from 90 mM rac-PGME and 20 mM 6-APA were 
carried out over a 10 hour time period, with samples taken at least every hour.  The 
results from these reactions are shown in Table 4.1.  From these reactions we were able to 
confirm that the three variants that showed improved (R)-selectivity as assayed by the 
well-plate screen, variants βPhe24Cys, βPhe24Pro, and βPhe24Ser, do in fact show 
improved selectivity towards (R)-ampicillin synthesis.  Additionally, we discovered that 
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variant βPhe24Ala also shows increased selectivity towards (R)-ampicillin synthesis.  
Furthermore, we were able to confirm that four of the variants that showed improved (S)-
selectivity as assayed by the well-plate screen, variants αPhe146Ala, αPhe146Arg, 
αPhe146Gln, αPhe146Tyr, show improved selectivity towards (S)-ampicillin.  Variant 
αPhe146Thr showed unexpected behavior, as the selectivity is conversion-dependent.  
The remaining variants identified by our library screening effort, which include 
αPhe146Lys, βPro22Asn, βPro22Leu, and βThr68Ser, exhibited either very low activity 
or low selectivity and were not studied further.   Ampicillin conversion profiles for wild-
type PGA, the most (R)-selective variant, the most (S)-selective variant, and for the 
variant that exhibits conversion-dependent selectivity is shown in Figure 4.3. 
 Perhaps the most obvious trend observed in selective mutants is that all variants 
that have improved selectivity for (R)-ampicillin synthesis result from an amino acid 
change at the β24 position and all variants that have improved selectivity for (S)-
ampicillin synthesis result from an amino acid change at the α146 position.  The crystal 
structure of wild-type PGA complexed with (R)-α-methyl phenylacetic acid (PDB 1K79) 
shows that βPhe24 and αPhe146 are on opposite sides of the substrate’s Cα, so it is 
consistent to expect that changes in these positions could lead to enhancements in 





Table 4.1: Results from ampicillin synthesis reactions starting from 90 mM rac-PGME and 20 mM 6-APA resulting in the production of (R)-ampicillin ((R)-
AMP) and (S)-ampicillin ((S)-AMP).   









































AMP Total Total 
WT PGA 37% - 0.086 1.00 0.048 1.00 0.135 1.00 21.0% 1.00 9.7% 1.00 30.7% 1.00 
Variants Selective for (R)-Ampicillin Synthesis 
βPhe24Ala 98% - 0.082 0.95 2.15E-04 0.00 0.082 0.61 42.4% 2.02 0.4% 0.04 42.8% 1.39 
βPhe24Ser 97% - 0.036 0.42 2.37E-04 0.00 0.036 0.27 35.0% 1.66 0.5% 0.05 35.5% 1.15 
βPhe24Pro 95% - 0.018 0.20 4.58E-04 0.01 0.018 0.13 26.5% 1.26 0.7% 0.07 27.2% 0.88 
βPhe24Cys 70% - 0.007 0.08 1.60E-03 0.03 0.009 0.06 15.0% 0.71 2.7% 0.28 17.7% 0.57 
Variants Selective for (S)-Ampicillin Synthesis 
αPhe146Ala - 51% 0.002 0.03 0.036 0.75 0.038 0.28 3.3% 0.16 10.2% 1.05 13.5% 0.44 
αPhe146Gln - 57% 1.06E-03 0.01 0.006 0.12 0.007 0.05 2.8% 0.14 10.3% 1.06 13.2% 0.43 
αPhe146Arg - 65% 5.76E-04 0.01 0.004 0.08 0.004 0.03 1.8% 0.09 8.6% 0.88 10.4% 0.34 
αPhe146Tyr - 36% 0.003 0.04 3.26E-03 0.07 0.006 0.05 1.7% 0.08 3.5% 0.36 5.1% 0.17 
Variants that Exhibit Conversion-Dependent Selective Behavior 
αPhe146Thr - - 0.043 0.49 0.116 2.40 0.158 1.17 34.1% 1.62 2.2% 0.22 36.3% 1.18 
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4.3.2.1 Variants Selective for (R)-Ampicillin Synthesis 
 Crystal structures of wild-type PGA and βPhe24Ala complexed with (R)-α-methyl 
phenylacetic acid (PDB 1K79 and 1K5S, respectively) show that the mutation does not 
result in significant positional rearrangement of the catalytic residues or the loop 
containing the β24 residue.  Furthermore, the two crystal structures show that the removal 
of a phenyl ring creates space in the binding pocket to better accommodate Cα-substituted 
(R)-enantiomers in comparison to wild-type PGA, explaining the 10-fold higher binding 
affinities observed by Alkema et al. for variant βPhe24Ala as compared to those observed 
for wild-type PGA for Cα-substituted substrates [7].  It is reasonable to assume that 
alanine, serine, and cysteine would have similar structural impacts.  That being said, the 
d.e.R values reported in Table 4.1 for βPhe24Ala, βPhe24Ser and βPhe24Cys correlate 
directly with the sizes of the amino acids present in each variant.  Alanine occupies the 
least amount of space, 88.6 Å3 [12], and is the most selective variant with a d.e.R value of 
98%.  Serine is not much larger; it occupies a volume of 89.0 Å3 [12], and is only slightly 
less selective with a d.e.R value of 97%.  Cysteine is considerably larger; it occupies a 
volume of 117.7 Å3 [12], and as a result is less selective with a d.e.R value of 70%.  
Variant βPhe24Pro does not follow this trend, though inserting a proline would affect the 
backbone structure of the protein, likely kinking the loop containing reside β24 and 
creating additional space in the binding pocket.  This would explain why βPhe24Pro has 
a d.e.R value of 95% despite occupying 122.7 Å3 of space [12].  Furthermore, the crystal 
structures of variant βPhe24Ala show that when a substituent on the Cα is present, the 
enzyme occupies the closed confirmation where αPhe146 shifts and covers the binding 
pocket [7].  As a result, αPhe146 occupies space that (S)-substituents would occupy, 
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explaining why βPhe24Ala, βPhe24Ser, βPhe24Pro, and βPhe24Cys, show significantly 
decreased (S)-ampicillin synthetic activity.    
 
4.3.2.2 Variants Selective for (S)-Ampicillin Synthesis 
 The amino acid substitutions at the α146 position that lead to an increase in 
selectivity for (S)-ampicillin synthesis are all very different.  As shown in Table 4.1, the 
most selective variant is αPhe146Arg with a d.e.S value of 65%, followed by αPhe146Gln 
with a d.e.S value of 57%, αPhe146Ala with a d.e.S value of 51%, and αPhe146Tyr with a 
d.e.S value of 36%.  Obviously, there is no trend in the observed selectivity of these 
variants with polarity, charge, or size of the amino acids, rendering it difficult to ascertain 
what factors are contributing to the observed increase in selectivity.  Similarly, Jager et 
al. found it difficult to correlate properties of the amino acids introduced at the α146 
position to their effects on the kinetic properties of PGA [13].  However, it is well known 
from crystal structures of PGA that the residue at the α146 position is flexible and can 
adopt multiple energetically favored conformations.  In the wild-type enzyme, the 
movement of αPhe146 is thought to occur either to create space in the binding pocket to 
accommodate larger substrates or to create additional binding interactions with the 
substrate, depending on the situation [7].  A crystal structure for αPhe146Tyr complexed 
with (R)-α-methyl phenylacetic acid shows no conformational changes in comparison to 
the wild-type, but because the position of αPhe146 is situational no certain conclusions 
can be drawn from it [7].  The variants that show increased selectivity for (S)-ampicillin 
synthesis are likely those that are able to adopt energetically favorable conformations that 
accommodate the (S)-substituent. 
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4.3.2.3 Variants that Exhibit Conversion-Dependent Selective Behavior   
 Variant αPhe146Thr shows interesting behavior as its observed selectivity is 
dependent on the extent of the reaction.  Initially the variant is selective for (S)-ampicillin 
synthesis with an initial d.e.S value of 67% at 10% yield.  However, the resulting (S)-
ampicillin produced by the enzyme is consumed by secondary hydrolysis while (R)-
ampicillin synthesis proceeds, resulting in a switch in selectivity and a d.e.R value of 88% 
at 36% yield.  This phenomenon is thought to be the result of altering the enzyme’s 
inhibition for either (S)-phenylglycine ((S)-PG) or (S)-ampicillin.  Although not 
confirmed, examining the reaction profiles that result from reactions with pure (R)-
PGME, pure (S)-PGME and rac-PGME has led us to hypothesize that wild-type PGA is 
inhibited by either (S)-ampicillin or (S)-PG.  This could explain why very little secondary 
hydrolysis of (S)-ampicillin is observed in reactions with the wild-type as compared to 
the αPhe146Thr variant. Inhibition studies for (S)-ampicillin and (S)-PG with wild-type 
PGA and αPhe146Thr would need to be completed to confirm this hypothesis.   
 
4.3.3 Ampicillin Synthesis from Pure Substrates 
 The nine interesting mutants were further characterized by investigating their 
ability to synthesize (R)-ampicillin and (S)-ampicillin from pure substrates over a 24 hour 
time period, with samples taken at least every two hours for the first 12 hours.  The 
results from the ampicillin synthesis reactions starting with 20 mM 6-APA and 60 mM 
(R)-phenylglycine methyl ester ((R)-PGME) are shown in Table 4.2 and Figure 4.4.  The 
results for ampicillin synthesis reactions starting from 20 mM 6-APA and 60 mM (S)-




















  (R)-PG (R)-PG (R)-AMP (R)-AMP (R)-AMP (R)-AMP 
WT PGA 0.325 1.00 0.256 1.00 0.79 38.2% 1.00 
Variants Selective for (R)-Ampicillin Synthesis 
βPhe24Ala 0.083 0.26 0.278 1.09 3.35 85.7% 2.24 
βPhe24Ser 0.065 0.20 0.133 0.52 2.04 82.7% 2.17 
βPhe24Pro 0.065 0.20 0.127 0.50 1.95 74.4% 1.95 
βPhe24Cys 0.033 0.10 0.050 0.19 1.49 42.7% 1.12 
Variants Selective for (S)-Ampicillin Synthesis 
αPhe146Ala 0.046 0.14 0.015 0.06 0.33 35.7% 0.93 
αPhe146Gln 0.039 0.12 0.004 0.02 0.11 16.2% 0.42 
αPhe146Arg 0.039 0.12 0.002 0.01 0.06 9.6% 0.25 
αPhe146Tyr 0.360 1.11 0.005 0.02 0.01 3.4% 0.09 
Variants that Exhibit Conversion-Dependent Selective Behavior 
αPhe146Thr 0.102 0.31 0.172 0.67 1.69 80.5% 2.11 



















  (S)-PG (S)-PG (S)-AMP (S)-AMP ratio (S)-AMP (S)-AMP 
WT PGA 0.073 1.00 0.090 1.00 1.23 18.5% 1.00 
Variants Selective for (R)-Ampicillin Synthesis 
βPhe24Ala 0.033 0.45 9.61E-04 0.01 0.03 2.6% 0.14 
βPhe24Ser 0.034 0.46 6.64E-04 0.01 0.02 1.6% 0.09 
βPhe24Pro 0.036 0.49 1.09E-03 0.01 0.03 2.4% 0.13 
βPhe24Cys 0.044 0.60 2.28E-03 0.03 0.05 3.4% 0.18 
Variants Selective for (S)-Ampicillin Synthesis 
αPhe146Ala 0.077 1.05 0.066 0.74 0.86 14.9% 0.80 
αPhe146Gln 0.053 0.72 0.015 0.16 0.28 13.6% 0.73 
αPhe146Arg 0.046 0.63 0.009 0.10 0.19 11.8% 0.64 
αPhe146Tyr 0.085 1.16 0.010 0.11 0.12 6.1% 0.33 
Variants that Exhibit Conversion-Dependent Selective Behavior 
αPhe146Thr 0.125 1.72 0.276 3.08 2.20 21.2% 1.15 
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4.3.3.1 Variants Selective for (R)-Ampicillin Synthesis 
 The (R)-selective variants that we have identified have proven to not only be more 
selective, but also lead to an enhancement in the yield achieved when synthesizing 
ampicillin from pure (R)-PGME as shown in Table 4.2.  The synthesis with variant 
βPhe24Ala results in the highest yield, 85.7%, and has increased synthetic activity over 
wild-type PGA by a factor of 1.09.  These results agree with the 3-fold increase in yield 
and the equivalent activity observed during ampicillin synthesis for βPhe24Ala in 
comparison to wild-type PGA that has been reported by Alkema et al. and the 4-fold 
increase in yield observed by Gabor et al. for a βPhe24Ala variant from penicillin acylase 
PAS2 [10, 14].  Variant βPhe24Ser has decreased synthetic activity in comparison to the 
wild-type PGA by a factor of 0.52, but is ultimately still able to achieve a yield of 82.7%.  
Similarly, βPhe24Pro has decreased synthetic activity in comparison to the wild-type 
PGA by a factor of 0.50 but yields 74.4% of ampicillin.  Finally, βPhe24Cys shows 
decreased synthetic activity by a factor of 0.19 in comparison the wild-type but still 
achieves a yield of 42.7%.  The trend in our results are similar to those reported when 
You et al. site-saturated βPhe24 and found the synthetic activity for βPhe24Ala to be 
330% relative to wild-type PGA, βPhe24Ser to be 23%, βPhe24Pro to be 31%, and 
βPhe24Cys to be 0% for cefadroxil synthesis from (R)-p-phenylglycine hydroxy ethyl 
ester and 7-aminodeacetoxycephalosporanic acid [15].  Closer examination of the data 
shows that all of the (R)-selective variants have significantly decreased hydrolytic 
activity.  As a result, we observe notably increased ratios of the synthesis of ampicillin to 
the generation of (R)-phenylglycine ((R)-PG) from primary hydrolysis, also known the 
synthesis to hydrolysis ratio (S/H-ratio), for the (R)-selective PGA variants as compared 
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to wild-type PGA.  An increase in the S/H-ratio is known to increase the yield in the 
kinetically-controlled synthesis of ampicillin, explaining why the (R)-selective variants 
show an improvement in yield despite decreases in their synthetic activity.  Also 
contributing to the yield enhancement is the considerable decrease in secondary 
hydrolysis observed, which is shown in Figure 4.4.  The work by Alkema et al. supports 
these findings for βPhe24Ala as they report a 4-fold decrease in kcat/KM for ampicillin in 
comparison to wild-type PGA and the 20-fold decrease in kcat/KM for ampicillin with a 
βPhe24Ala variant from penicillin acylase PAS2  [10, 14]. 
 The (R)-selective variants result in a significantly decreased hydrolytic activity, 
synthetic activity, and yield when synthesizing ampicillin from (S)-PGME as shown in 
Table 4.3.  The most interesting result from this set of experiments is that the (R)-
selective variants actually produced (R)-ampicillin when starting from pure (S)-PGME. 
After 24 hours, variant βPhe24Ala yielded 8.0% (R)-ampicillin, βPhe24Ser yielded 8.3% 
(R)-ampicillin, βPhe24Pro yielded 6.6% (R)-ampicillin, and βPhe24Cys yielded (R)-
ampicillin.  As shown in Figure 4.5, the rate that βPhe24Ala catalyzes (R)-ampicillin 
synthesis is 1.5-fold faster than the rate that it catalyzes (S)-ampicillin synthesis, though 
(R)-ampicillin synthesis does not begin until 27 minutes after the reaction was initiated.  
Similarly, βPhe24Ser catalyzes (R)-ampicillin synthesis at 2.2 times the rate of (S)-
ampicillin, but (R)-ampicillin synthesis does not begin until 69 minutes after the reaction 
was initiated.  As our analytical techniques only separate diastereomers, it is unknown if 
these variants are acting as a racemases, epimerases, or both.  This type of behavior is 
only observed in the wild-type enzyme on long time scales and even then yields of (R)-
ampicillin are less than 1%.  Because we’ve never seen this type of behavior with the 
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wild-type enzyme on the time-scales we employ, we can also rule out the possibility that 
the racemization is occurring chemically.  This intriguing phenomenon is not understood 
and to our knowledge has never been reported for wild-type PGA or any PGA variants.  
 
4.3.3.2 Variants Selective for (S)-Ampicillin Synthesis 
 The (S)-selective variants that we have identified all show a decrease in hydrolytic 
activity, synthetic activity and yield achieved when synthesizing ampicillin from pure 
(R)-PGME and 6-APA.  However, similar to how the (R)-selective variants are able to 
catalyze (R)-ampicillin synthesis from (S)-PGME, the (S)-selective variants are able to 
catalyze (S)-ampicillin synthesis from pure (R)-PGME.  Variant αPhe146Ala yielded 
1.5% (S)-ampicillin, αPhe146Gln yielded 5.4% (S)-ampicillin, αPhe146Arg yielded 4.4% 
(S)-ampicillin, and αPhe146Tyr yielded less than 1% (S)-ampicillin.  The (S)-selective 
variants catalyze (S)-ampicillin synthesis at much slower rates than they synthesize (R)-
ampicillin when starting from pure (R)-PGME, nonetheless the fact that these PGA 
variants can act as a racemase or epimerase is fascinating. 
 The (S)-selective variants also show a decrease in synthetic activity and yield in 
the synthesis of ampicillin from (S)-PGME and 6-APA compared to wild-type PGA.  As 
discussed above, the S/H-ratio is an indicator of the overall yield in the kinetically-
controlled synthesis of ampicillin, and the (S)-selective variants have a decreased S/H-
ratio for all synthesis reactions from pure substrates.  This is in contrast to previous 
reports that αPhe146Ala has a two-fold increase in (S/H)-ratio but activity so low that a 
reliable concentration for ampicillin could not be determined in the synthesis from 15 
mM (R)-PGA and 30 mM 6-APA.  Furthermore, these results differ from those reported 
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by Jager et al. for ampicillin synthesis from 15 mM (R)-phenylglycine amide ((R)-PGA) 
and 10 mM 6-APA.  Jager et al. site-saturated αPhe146 and found that αPhe146Ala 
achieved 99% of the maximum yield of wild-type PGA, αPhe146Gln achieved 114%, 
αPhe146Arg achieved 3% and αPhe146Tyr achieved 0% for ampicillin synthesis from 15 
mM (R)-PGA and 10 mM 6-APA [13].  This clearly corroborates previous reports that 
esterase and amidase activity are not necessarily equivalent [14].  The most drastic 
decrease in S/H-ratio is observed for αPhe146Tyr, which has decreased nearly 60-fold in 
the synthesis from (R)-PGME and decreased 10-fold in the synthesis from (S)-PGME, 
agreeing with previously reported results of a 40-fold decrease in S/H-ratio for the 
synthesis of ampicillin from (R)-PGA and 6-APA [14].  In all cases, the decrease in the 
S/H-ratio can be explained by the fact that αPhe146 is known to have van der Waals 
interactions with the β-lactam nucleus.  Therefore mutating this residue will decrease the 
affinity of the enzyme for 6-APA and thereby decrease the synthesis activity of the 
enzyme.   
 
4.3.3.3 Variants that Exhibit Conversion-Dependent Selective Behavior   
 αPhe146Thr shows an increase in yield for (R)-ampicillin synthesis starting from 
pure (R)-PGME and an increase in yield for (S)-ampicillin synthesis starting from pure 
(S)-PGME.  For the reactions starting from 6-APA and pure (R)-PGME, the variant 
shows decreased synthetic activity by a factor of 0.67 and decreased hydrolytic activity of 
0.31, leading to an improved S/H-ratio and therefore a yield increase to 80.5%.  In 
contrast, for the reaction starting from 6-APA and pure (S)-PGME, αPhe146Thr shows 
increased hydrolytic activity by a factor of 1.72 and increased synthetic activity by a 
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factor of 3.08, also resulting in an increase in the synthesis to hydrolysis activity and an 
improved yield of 21.2% (S)-ampicillin.  An improvement in S/H-ratio and yield has 
been previously reported for αPhe146Thr [13].  αPhe146Thr exhibits racemase or 
epimerase activity, though in yields less than 1% for both reactions from pure substrates. 
 
 
Table 4.4: NIPAB hydrolysis by PGA variants  
  Vmax Relative Vmax KM Relative KM 
  (μmol NABA/min mg PGA)   (μM)   
WT PGA 17.3 1.00 26.0 1.00 
Variants Selective for (R)-Ampicillin Synthesis 
βPhe24Ala 1.0 0.06 98.2 3.77 
βPhe24Ser 0.6 0.04 550.9 21.18 
βPhe24Pro 2.9 0.17 796.5 30.61 
βPhe24Cys ND[a] ND ND ND 
Variants Selective for (S)-Ampicillin Synthesis 
αPhe146Ala 7.3E-02 4.2E-03 115.9 4.45 
αPhe146Gln 4.9E-02 2.8E-03 271.7 10.44 
αPhe146Arg 5.3E-02 3.1E-03 386.2 14.84 
αPhe146Tyr 1.3 0.08 0.5 0.02 
Variants that Exhibit Conversion-Dependent Selective Behavior 
αPhe146Thr 2.5E-01 0.01 78.5 3.02 




4.3.4 2-Nitro-5-[(Phenylacetyl)amino]-Benzoic Acid Hydrolysis 
 All nine mutants were further characterized by investigating their ability to 
hydrolyze 2-nitro-5-[(phenylacetyl)amino]-benzoic acid (NIPAB) and the results are 
shown in Table 4.4.  NIPAB is a chromogenic analog of penicillin G and is widely used 
to characterize the hydrolysis activity of PGA variants.  With the exception of 
αPhe146Tyr, all of the variants had significantly decreased hydrolytic activity and 
binding affinities for NIPAB as evidenced by hugely increased KM values.  This agrees 
with the results that Alkema et al. presented for variants βPhe24Ala, αPhe146Ala, 
αPhe146Tyr, and supports the hypothesis that the removal of a phenyl ring from the 
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active site of PGA decreases the binding affinity for its substrates [4, 14].  Previous 
reports indicate that only Cα-substituted substrates bind tightly to βPhe24Ala [7]. The 
amino acid variation at βPhe24Ser and βPhe24Cys are assumed to have structural 
impacts equivalent to βPhe24Ala and therefore the lack of a Cα substituent would 
contribute to their low binding affinities for NIPAB as well.   
 
4.4 Conclusions  
 In this work, we succeeded in altering the diastereomeric selectivity of PGA by 
site-saturating five residues in the active site.  Four PGA variants were found to have 
improved selectivity for (S)-ampicillin synthesis, all resulting from an amino acid 
substitution at the α146 position.  The position of the residue at α146 is known to be 
flexible and depend on the substrate bound, and therefore it is difficult to ascertain what 
factors led to the observed (S)-selective behavior. In the wild-type enzyme αPhe146 is 
known to interact with the β-lactam nucleus and therefore the synthetic activity of the 
variants was affected as evidence by the decreased S/H-ratio and a decrease yield for the 
synthesis (R)-ampicillin and (S)-ampicillin from (R)-PGME and (S)-PGME, respectively, 
for all mutants. 
 Finding a PGA variant capable of asymmetrically synthesizing (R)-ampicillin 
would enable the use of racemic activated acyl side chains in the synthesis of ampicillin, 
cephalexin and cefaclor.  We have discovered four (R)-selective variants with improved 
diastereomeric selectivity for (R)-ampicillin synthesis.  The result is an improvement 
from the d.e.R value of 37% for the wild-type enzyme to a d.e.R value of 98% for our 
most selective mutant, βPhe24Ala.  All (R)-selective variants resulted from an amino acid 
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substitution at the β24 position and the extent of selectivity was shown to be dependent 
on the size of the amino acid substituted.  Additionally, the (R)-selective variants were 
shown to have up to 4-fold decreases in S/H-ratio and up to 2-fold increases in the yield 
achieved when synthesizing ampicillin from pure (R)-PGME.     
 Even if the initial activated acyl side chain of choice for ampicillin is (R)-PGA, 
these variants can prove to be useful in the synthesis of semi-synthetic β-lactam 
antibiotics.  The production of pure (R)-PGA from rac-phenylglycine amide with L-
aminopeptidase results in a maximum of 50% conversion to the desired (R)-PGA and an 
excess of the (S)-PG.  (S)-PG is can be racemized and resolved with diastereomeric salt 
crystallization, or alternatively it can be esterified and racemized in one step with the use 
of naphtha cracking catalyst zeolite H-USY [16].  A dynamic kinetic resolution by 
selective ammonolysis of rac-PGME with Candida antarctica lipase B coupled with 
racemization with an aromatic aldehyde to selectively produce (R)-PGA has been 
previously proposed but has not been implemented because it only achieves and 
enantiomeric excess of 85% [17].  Replacing the lipase with a selective PGA would 
eliminate the need for the ammonolysis step, as PGA could synthesize ampicillin directly 
from the methyl ester, and the dynamic kinetic resolution nature of the process would be 
retained.   
 
4.5 Publication Information 
 The research presented in Chapter 4 of this dissertation was submitted to Protein 
Engineering Design and Selection by August 10th, 2011 for publication with Janna K. 
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5.1 Summary and Conclusions 
 The work presented in this dissertation encompasses reaction engineering, 
medium engineering, and data-driven protein engineering, to improve the enzymatic 
synthesis of semi-synthetic β-lactam antibiotics.  Our studies focused on the kinetically-
controlled synthesis of ampicillin, though the results are likely applicable to the synthesis 
of amoxicillin, cephalexin, cefadroxil, cefaclor and cefprozil.   
 Reaction engineering was employed to demonstrate the feasibility of utilizing a 
cascade conversion involving two biocatalytic steps in fully aqueous medium to produce 
ampicillin.  A cascade set-up presents a promising alternative to the current two-pot set-
up which requires intermittent isolation of the intermediate, 6-aminopenicillanic acid (6-
APA).  In the first reaction, the β-lactam moiety 6-APA was produced from the 
thermodynamically-controlled hydrolysis of penicillin G with immobilized PGA.  The 
byproduct from this reaction, phenylacetic acid (PAA), is a known inhibitor of PGA [1].  
In the second reaction, ampicillin was produced from the kinetically-controlled coupling 
of 6-APA and (R)-phenylglycine methyl ester ((R)-PGME) catalyzed by either PGA or α-
amino ester hydrolase (AEH) [2].  AEHs are unique in their specificity for α-amino 
groups on the acyl moiety and therefore do not catalyze the hydrolysis of penicillin G and 
are not inhibited by PAA [3].  In this work, two different reaction configurations and 
various relative enzyme loadings were studied.   
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 In all reaction configurations the two-enzyme system that utilized PGA and AEH 
out-performed the one-enzyme system that utilized only PGA.  Furthermore, it was 
determined that relative enzyme loadings had a large effect on the maximum yield 
achieved and the degree of secondary hydrolysis observed.  In a one-pot, one-step 
configuration, a batch process, penicillin G, (R)-PGME, and all enzyme(s) were added to 
the reaction and the reaction was allowed to proceed.  The optimum enzyme loading was 
determined to be 99.2 UPenG PGA and 4.4 UAmp AEH which resulted in a maximum 
yield of 39% achieved in 60 minutes.  In a one-pot, two-step configuration, penicillin G 
and PGA were added to the reaction and the hydrolysis reaction was allowed to proceed.  
When the hydrolysis reaction was near completion, (R)-PGME and either AEH or PGA 
was added to the reaction.  The optimum enzyme loading was determined to be 99.2 
UPenG PGA and 4.4 UAmp AEH which resulted in a maximum yield of 46% after 150 
minutes.   
 Medium engineering is studied in β-lactam antibiotic synthesis to suppress 
undesired primary and secondary hydrolysis reactions. Ampicillin synthesis reactions 
from 6-APA and (R)-PGME in the 30% (v/v) ethylene glycol revealed that ethylene 
glycol reacts with (R)-PGME to form (R)-phenylglycine hydroxyethyl ester ((R)-PGHEE.  
The formation of (R)-PGHEE has never been reported or studied.  The present work 
investigates the synthesis of ampicillin from different acyl donors in systems containing 
ethylene glycol, ethanol and tert-butyl alcohol, to test the hypothesis that 
transesterification of a side chain acyl donor with a co-solvent can act as an in-situ mixed 
donor synthesis and can positively affect yield.  The transesterification of (R)-PGME to 
(R)-PGHEE rather than hydrolysis of (R)-PGME to (R)-PG re-directs the consumption of 
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(R)-PGME to an intermediate that could be used to synthesize ampicillin, rather than to 
an unusable hydrolysis side product.  
 When (R)-PGME is used as the activated acyl side chain, we have observed that 
the ampicillin yield enhancement is dependent on the amount of (R)-PGME present in the 
reactions.  When (R)-PGA is used at the activated acyl side chain, we have found that the 
use of ethylene glycol as a co-solvent has minimal effects on the yield of ampicillin 
achieved.  Furthermore, we have synthesized (R)-PGHEE and shown that it can act as an 
acyl side chain donor for the synthesis of ampicillin.  Based on these results, there is 
evidence that the synthesis of ampicillin from (R)-PGME and 6-APA with an ethylene 
glycol co-solvent acts as an in situ mixed donor synthesis, where both (R)-PGME and 
(R)-PGHEE are acyl side chain donors for the synthesis of ampicillin. 
 Protein engineering was utilized to improve the diastereomeric selectivity of PGA 
so that racemic acid derivatives can be used in β-lactam antibiotic synthesis.  When 
starting with rac-PGME, PGA will catalyze the synthesis of the desired product, (R)-
ampicillin, in addition to an undesired product, (S)-ampicillin, exhibiting only weak 
selectivity for the desired product.  Using PGA crystal structures, we targeted residues for 
mutation based on the proximity to the substrate’s chiral center.    
 We identified four variants with improved selectivity for (R)-ampicillin synthesis, 
all resulting from a mutation at the β24 position.  The most selective mutant improved the 
d.e.R value of 37% for the wild-type enzyme to a d.e.R value of 98% for our most 
selective mutant, βPhe24Ala.  Also, we identified four variants with muatations at the 
α146 position that resulted in (S)-selective PGA variants.  βPhe24 and αPhe 146 are on 
opposite sides of the alpha carbon of PGME, and we have shown that altering these 
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residues results in enhanced selectivities in opposite directions.  All variants that showed 
selectivity for (S)-ampicillin synthesis showed decreased synthetic activity for racemic 
pure substrates, likely as a result of increasing the synthesis to hydrolysis ratio by altering 
the interaction of αPhe146 with the β-lactam nucleus.  In contrast, the mutants that were 
selective for (R)-ampicillin showed significantly decreased primary and secondary 
hydrolysis when synthesizing ampicillin from pure (R)-PGME, resulting 4-fold decreases 
in S/H-ratio and up to 2-fold increases in the yield achieved.  Finally, we have discovered 
that the PGA variants have racemase or epimerase activity, a fascinating phenomenon 
that has never been reported and should be studied further.   
 Overall, we have improved the enzymatic synthesis of semi-synthetic β-lactam 
antibiotics by extending the understanding and applications of the biocatalysts that are 
utilized to synthesize them.  We have elucidated an in-situ mixed donor synthesis that is 
the result of ampicillin synthesis in the presence of select acyl side chain donors and 
suitable co-solvents.  We have shown that AEH and PGA can be combined in a novel 
cascade synthesis to eliminate one of the isolation steps in the current manufacturing 
process.  Finally, we have made significant progress towards developing a selective PGA 
that would allow the use of racemic substrates to produce diastereomerically pure β-
lactam antibiotics and eliminate the need to use enantiomerically pure substrates for their 
synthesis. Eliminating isolation and purification steps represent significant improvements 









5.2 Recommendations  
 
5.2.1 Further Improvements to Penicillin G Acylase Selectivity 
 
 In Chapter 4 of this dissertation we used data-driven protein engineering 
techniques to improve the diastereoselectivity of penicillin G acylase (PGA) for the 
synthesis of (R)-ampicillin from 6-aminopenicillanic acid (6-APA) and rac-
phenylglycine methyl ester (rac-PGME).  Specifically, we were successful in increasing 
the diastereomeric excess (d.e.) value in the (R)-direction from 37% that the wild-type 
PGA exhibits to a d.e.R value of 98% for the most selective PGA variant, βPhe24Ala.  
However, any presence of (S)-ampicillin in the final drug product would be considered an 
impurity and the United States Food and Drug Administration’s requires that all organic 
impurities above 0.1% should be isolated and characterized with full toxicology studies 
[4].  Therefore, while these results represent significant progress, even further 
improvements to the selectivity of PGA should be investigated to improve the d.e.R value 
of PGA to greater than 99.8%.   
 
5.2.1.1 Continued Use of Data-Driven Protein Engineering Techniques 
Given the success of utilizing data-driven techniques for the present work, we 
propose that data-driven protein engineering techniques should continue to be employed 
to further push PGA towards the desired selectivity.  With an improved variant of PGA 
already in hand, the next protein engineering technique that should be exercised is 
iterative saturation mutagenesis (ISM).  ISM aims to improve a protein for a desired 
characteristic incrementally, taking the best variant from site-saturation at one residue 
and further improving it by using the improved variant as the template for site-saturation 
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at another residue [5].  ISM has proven to be successful for improving thermostability of 
Bacillus subtilis lipase A and enantioselectivity of an epoxide hydrolase from Aspergillus 
niger [5]. 
 A subset of ISM that can also be employed is combinatorial active site saturation 
testing (CASTing).  This method generates a library by randomization at several sets of 
two or three spatially close residue positions.  The groups are chosen based on their 
secondary structure which allows for possible synergistic effects to be seen.  The above 
stated example of improving the enantioselectivity of an epoxide hydrolase from 
Aspergillus niger utilized CASTing [6].   
 
5.2.1.2 Residues to Target for Further Improvements to Penicillin G Acylase Selectivity 
In the work presented in this dissertation, we improved the selectivity of PGA by 
site-saturating residues within 6 Å of the alpha carbon (Cα) of the inhibitor penicillin G 
sulfoxide with NNK libraries.  Since we have not exhausted the first and second shell 
residues in the active site of PGA, residues should continue to be chosen based on their 
proximity to the Cα of  penicillin G sulfoxide for ISM to further improve the selectivity of 
PGA.  In addition to the 6 residues that have already been chosen, there are 11 additional 
residues that are within the 8 Å that should be targeted for mutation.  Again, residues that 
are known to be necessary for catalysis should not be considered for mutation.  The 11 
residues are shown in Figure 5.1 and listed with their secondary structures in Table 5.1.  
Of the residues that have not already been investigated, only αThr141 and αArg145 could 
be combined to form a CAST library.  Alternatively, the residues that have not been 
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5.2.1.3 Potential Obstacles  
 We have experience in creating and screening diverse NNK libraries for single 
residues and therefore, we expect obstacles for site-saturation at one position to be 
minimal.  However, if CASTing libraries were chosen for study, efforts should be taken 
to make screening more feasible.  The current choice of utilizing a NNK restricted library 
that codes for 32 codons requires screening of at least 94 mutants for saturation at one 
position in order to guarantee that the libraries are covered with greater than 95% 
confidence .  If two residues were chosen for simultaneous NNK site-saturation, 3066 
mutants would need to be screened to cover the library space with greater than 95% 
confidence.  In the present work we used an ampicillin synthesis-based HPLC assay that 
required 40 minutes screening per mutant.  For 94 mutants, the assay is arduous, but 
feasible.  For 3066 mutants, the current HPLC screen method would be extremely time-
consuming.  A possible solution would be to use a further restricted NDT codon library 
(N represents an equal mixture of the nucleotide bases A, G, C, and T; D represents an 
equal mixture of A, G, and T) when simultaneous saturation at two positions is desired.  
NDT libraries code for a diverse set of 12 amino acids instead of all 20 proteinogenic 
amino acids that NNK libraries code for.  However, switching to a NDT library would 
reduce the number of condons to 12 and the number of mutants required to be screened 
for greater than 95% coverage to 430.   
 
5.2.2 Decouple Reactions in Kinetically-Controlled Synthesis of Ampicillin with 
Racemic and Pure Substrates to Further Study Selective PGA Variants 
 
 As discussed in Chapter 4 of this dissertation, we have found that the selective 
PGA variants that we have identified have racemase or epimerase activity.  Such activity 
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has never been reported for PGA or any PGA variant.  This phenomenon is fascinating, 
but cannot be explained with existing knowledge of PGA.  At this point we are not even 
able to determine if the enzyme is acting as a racemase or an epimerase because our 
current analytical capabilities only allow us to distinguish between diastereomers.  To 
begin to understand this phenomenon, chiral analytical techniques must be pursued and 
the reactions in the kinetically-controlled synthesis of ampicillin must be decoupled to 
paint a clearer picture of the system.    
 
5.2.2.1 Development of Chiral High Performance Liquid Chromatography Analysis 
 A number of Astec CHIROBIOTIC® T Chiral HPLC Columns that employ 
teicoplanin as a chiral selector to separate amino acids are readily available from Sigma 
Aldrich (St. Lous, MO, USA).  The method must analyze for seven components – (R)-
phenylglycine ((R)-PG), (S)-phenylglycine ((S)-PG), (R)-ampicillin, (S)-ampicillin, (R)-
phenylglycine methyl ester, (S)-phenylglycine methyl ester, and 6-APA.   
 With a chiral HPLC method in hand, the reactions should be decoupled as 
follows: (1) hydrolysis of rac-PGME to form (R)-PG and (S)-PG; (2) hydrolysis of rac-
ampicillin to form 6-APA, (R)-PG, and (S)-PG; and (3) synthesis of ampicillin from rac-
PGME and 6-APA to form (R)-ampicillin and (S)-ampicillin.  After the reactions are 
decoupled, it will be clear if the enzyme has racemase activity or epimerase activity or 






5.2.2.2 Potential Obstacles    
 (S)-ampicillin is not readily available, so it will need to be synthesized and 
purified.  We are able to synthesize (S)-ampicillin enzymatically with the use of wild-
type PGA as discussed in Chapter 4, albeit at low yields.  The main obstacle that will be 
encountered is how to isolate (S)-ampicillin given its high solubility in the presence of 
phenylglycine.  DSM (Delft, Netherlands) reports that the isolation of ampicillin is 
accomplished by acidification of the reaction mixture followed by a selective 
crystallization with a pH shift [7].  A potential solution would be to study amoxicillin as 
opposed to ampicillin.  The variant βPhe24Ala has been previously reported to have a 
higher kcat/Km for (R)-p-hydroxyphenylglycine methyl ester, the side chain acyl donor for 
amoxicillin, than it does for (R)-PGME, the side chain acyl donor for ampicillin [8].  
Therefore, such a switch should not be limited by substrate specificity.  The isolation of 
amoxicillin is much easier than ampicillin because its solubility is much lower, and 
therefore the crystalline product can be removed from the reaction mixture by filtration 
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HPLC Method:  
 
Shimadzu-LC-20AT pump, Beckman Coulter Ultrasphere ODS 4.6 mm x 25 cm column, 
and SPD-M20A prominence diode array detector monitored at 215 nm.  
 
Mobile phase was isocratic at 1.0 mL min−1 with 30% acetonitrile and 70% 5 mM 




(R)-phenylglycine / RT = 3.77 
6-aminopenicillanic acid / RT = 5.04 
(R)-phenylglycine hydroxyethyl ester / RT = 13.13 
(R)-ampicillin / RT = 15.61 




(R)-phenylglycine / RT = 3.96 
6-aminopenicillanic acid / RT = 5.20 
(R)-phenylglycine amide / RT = 10.68 
(R)-ampicillin / RT = 16.37 
  



































































































HPLC Method:  
 
Shimadzu-LC-20AT pump, Beckman Coulter Ultrasphere ODS 4.6 mm x 25 cm column, 
and SPD-M20A prominence diode array detector monitored at 215 nm.  
 
Mobile phase was isocratic at 1.0 mL min−1 that initially contained 12.5% methanol and 
87.5% 20 mM phosphate buffer at pH 7.0, increased via a step change to 30.0% methanol 
and 70% 20 mM phosphate buffer at pH 7.0 after 7 minutes, and decreased via a step 
change to 12.5% methanol and 87.5% 20 mM phosphate buffer at pH 7.0 after 30 min 




rac-phenylglycine / RT = 3.44 
6-aminopenicillanic acid / RT = 4.13 
(S)-ampicillin / RT = 14.32 
(R)-ampicillin / RT = 15.04 
rac-phenylglycine methyl ester / RT = 17.54 
  















































































2-Nitro-5-[(Phenylacetyl)amino]-Benzoic Acid Assay: 
The hydrolysis of NIPAB liberates 5-amino-2-nitrobenzoic acid, which was monitored at 
405 nm with a Beckmann-Coulter DU®800 spectrophotometer.  NIPAB hydrolysis 
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